Document:

Manufacturing and Supply Agreement

 Exhibit 10.28 
 CONFIDENTIAL TREATMENT REQUESTED 
 MANUFACTURING AND SUPPLY AGREEMENT 
 THIS MANUFACTURING AND SUPPLY AGREEMENT is entered into as of April 3, 2008 (the “Effective Date”) by and between
DEXCOM, INC., a Delaware corporation, having an address of 6340 Sequence Drive, San Diego, California 92121 (“Purchaser”), and PTG MEDICAL LLC, a California limited liability company, with its principal office at 2810 Seventh
St., Berkeley, CA 94710 (“Supplier”). 
 RECITALS 
 WHEREAS, Purchaser is in the business of developing, manufacturing, marketing and selling continuous glucose monitoring products for people with
diabetes. 
 WHEREAS, Supplier is in the business of manufacturing and packaging specialty polymers and biomedical materials including
polymeric materials suitable for the manufacture and fabrication of Purchaser’s products; and 
 WHEREAS, Purchaser desires to
utilize Supplier as a contract manufacturer to manufacture, package, store and ship Materials (defined below) in accordance with the terms and conditions set forth herein. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
  

	1.	DEFINED TERMS. 

 1.1 “Acceptance
Period” shall have the meaning provided in Section 6.4(b). 
 1.2 “Adverse Event”
shall mean any adverse event associated with the use of any Materials, including an adverse event occurring in the course of the use of Materials in commercial practice, in studies, in investigations or in tests. 
 1.3 “Affiliate” shall mean, with respect to any party hereto, any entity that controls, is controlled by, or is
under common control with such party. For the purposes of this definition, a party shall be deemed to control another entity if it owns or controls, directly or indirectly, more than fifty percent (50%) of the voting equity of the other entity
(or other comparable ownership interest for an entity other than a corporation) and if it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of such other entity. 
 1.4 “Applicable Laws” shall mean all United States federal, state and local laws, statutes, rules, regulations,
ordinances (including any amendments thereto), applicable to the import, export, manufacture and distribution of the Materials. In the event of any conflict between the foregoing sources of authority, U.S. federal law and regulations shall be given
priority. 
 1.5 “Approval Application” shall mean an application for Regulatory Approval required
before commercial sale or use of the Materials in combination with any of Purchaser’s Products in any applicable regulatory jurisdiction. 
 1.6 “Certificate of Analysis” shall have the meaning provided in Section 3.4. 
  

 DexCom Confidential 

 ******CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 
  

 1.7 “Confidential Information” of a party shall mean all
information, including but not limited to product specifications, data, know-how, formulations, product concepts, sample materials, business and technical information, financial data, and deal terms, whether in written form or disclosed orally,
visually and/or in another tangible form, disclosed hereunder by such party to one or more other parties. 
 1.8
“Coordinator(s)” shall have the meaning provided in Article 2. 
 1.9 “First
Shipment” shall mean the date of the first commercial shipment of Materials to Purchaser. 
 1.10
“Forecast” shall have the meaning provided in Section 3.2. 
 1.11 “Governmental
Authority” shall mean any country, including any political subdivision thereof, court, instrumentality, or agency thereof, and any other federal, state, or public authority, domestic or foreign, exercising governmental powers and
having jurisdiction, and all statutes, laws, ordinances, regulations, orders, decrees, permits, writs, process and rules issued thereby which may be applicable to the parties’ performance under this Agreement. 
 1.12 “Invention” shall have the meaning provided in Section 7.2. 
 1.13 “Latent Defect” shall mean a defect that causes Materials to fail to conform to the Materials Specifications
or to the warranties provided by Supplier hereunder, which defect is not discoverable upon reasonable physical inspection and testing performed pursuant to Sections 3.4 and 6.4 but is discovered at a later time. 
 1.14 “Materials” shall mean Supplier’s polymeric materials meeting the Materials Specifications and the
Quality Systems, for use by Purchaser, its Affiliates or its sublicensees in the manufacture of Products. 
 1.15
“Materials Price” shall mean the price for Materials set forth in Exhibit B hereto, as such price may be adjusted from time to time in accordance with the terms of this
Agreement. 
 1.16 “Materials Specifications” shall mean the final specification of the Materials, as
set forth in Exhibit C. 
 1.17 “PPI” shall have the meaning provided in
Section 5.2. 
 1.18 “Product(s)” shall mean continuous glucose monitoring products for people
with diabetes which utilize Materials. 
 1.19 “Quality Statement” shall have the meaning provided in
Section 4.4. 
 1.20 “Quality Systems” shall mean the regulatory, manufacturing, quality control
and quality assurance procedures, processes, practices, standards, instructions and any other attributes that the parties agree upon or that are otherwise required in connection with the manufacture of Materials (including, without limitation any
requirements set forth in the Quality Agreement), as set forth in Exhibit D hereto (as such Exhibit may be amended by mutual agreement of Purchaser and Supplier from time to time). 
  

					
	DexCom Confidential	  	2	  	

 ******CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 
  

 1.21 “Regulatory Approval” shall mean any approvals (including
supplements, amendments, pre- and post—marketing approvals, and pricing and reimbursement approvals), licenses, registrations or authorizations of any national, supra-national (e.g., the European Commission or the Council of the European
Union), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, necessary for the manufacture, distribution, use or sale of Products containing the Materials in a regulatory jurisdiction.

 1.22 “Supplier’s Facility” shall mean the manufacturing facility or facilities at which Supplier shall
manufacture Materials. 
 1.23 “Third Party” shall mean any entity other than Purchaser or Supplier or an
Affiliate of either. 
 1.24 “Tooling and Equipment” means the equipment owned by Purchaser and provided to
Supplier to be used to manufacture Materials hereunder as identified on Exhibit A hereto. 
  

	2.	COORDINATORS. 

 Within ten (10) days after the
date hereof, Purchaser and Supplier shall each appoint an authorized representative and a back-up representative (each, a “Coordinator” and collectively, the “Coordinators”) for the exchange of all
communications, other than legal notices, related to the manufacturing, labeling and packaging of the Materials. Each such party shall provide notice to the other party as to the name and title of the individuals so appointed. Each party may replace
its coordinators at any time for any reason by providing written notice to the other party in accordance with Section 13.4. 
  

	3.	PURCHASE AND SUPPLY. 

 3.1 Purchase and Supply
Agreement. During the term of this Agreement, Purchaser agrees to buy, and Supplier agrees to use commercially reasonable efforts to sell, such quantities of Materials as may be set forth on purchase orders placed by Purchaser in accordance with
the provisions of Section 3.3. The transfer price for supply of Materials shall be as provided in Section 5.1. Supplier shall supply Materials to Purchaser on an exclusive basis and shall not have the right to manufacture for or to supply
Materials to any third party without written concurrence from Purchaser, which shall not be unreasonably withheld. Purchaser shall have the right to purchase similar materials from one or more Third Parties during the term of this Agreement if
Supplier fails to supply Materials that meet agreed upon specifications under the terms of this Agreement. 
 3.2 Forecasts.
Each calendar quarter, Purchaser shall provide Supplier with a written [*****] rolling forecast, by quarter, of its estimated orders for Materials (each a “Forecast”). Each Forecast is a non-binding estimate and shall not
obligate Purchaser to purchase the volume of Materials set forth in it; provided, however, that the volume forecasted for the first [*****]months of each Forecast shall represent Purchaser’s firm order for such Materials. Notwithstanding
any other provision of this Agreement to the contrary, Supplier shall not be obligated to manufacture or supply Purchaser with quantities of Materials in excess of 125% of the second [******] of the preceding forecast provided to Supplier in a
Forecast; provided, however, that Supplier agrees to use reasonable efforts to fill any order by Purchaser in excess of 125% of such Forecast. 
  

					
	DexCom Confidential	  	3	  	

 ******CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 
  

 3.3 Purchase Orders. Purchaser shall order Materials by submitting written purchase
orders, in such form as the parties shall agree from time to time, to Supplier specifying the quantities of each Materials ordered, the desired shipment date for such Materials, and any special shipping instructions. Purchaser shall order Materials
in lots of a defined number pursuant to each purchase order as specified by Supplier. Purchaser shall submit each purchase order to Supplier at least [******] in advance of the desired shipment date specified in such purchase order. Supplier shall
make each shipment of Materials in the quantity and before or up to [******]after the shipment date specified for it on Purchaser’s purchase order, via the mode(s) of transportation and to the party and destination specified on such purchase
order. Shipment shall be F.O.B. the Supplier Facility. Any purchase orders for Materials submitted by Purchaser to Supplier shall reference this Agreement and shall be governed exclusively by the terms contained herein. The parties hereby agree that
the terms and conditions of this Agreement shall supersede any term or condition in any order, confirmation or other document furnished by Purchaser or Supplier that is in any way inconsistent with these terms and conditions. 
 3.4 Materials Specifications; Testing. Materials supplied hereunder will conform to the Materials Specifications and Quality Systems (as
amended from time to time by written agreement between the parties) and such conformance will be verified in accordance with the testing standards and procedures specified therein. Supplier will test each batch of Materials and supply Purchaser with
a certificate of analysis (“Certificate of Analysis”) confirming that such meets the Materials Specifications. Purchaser may then retest the batch of Materials as more fully set forth in Sections 6.l and 6.4 to confirm that
it meets Materials Specifications. Accordingly, Purchaser and Supplier agree to negotiate in good faith to modify Materials Specifications from time to time as the parties’ experience with the manufacture, testing and use of Materials warrants;
and Supplier further agrees that it will make reasonable efforts to facilitate changes to Materials Specifications that are necessary or appropriate in light of regulatory requirements. The parties agree to allocate on an equitable basis any special
costs of developing and implementing revised procedures, including capital expenses. 
  

	4.	MANUFACTURE. 

 4.1 Tooling and Equipment. 

 (a) Tooling and Equipment to Supplier. Purchaser shall provide the tooling and equipment to Supplier listed
on Exhibit A hereto (“Tooling and Equipment”). All such Tooling and Equipment shall be sent to Supplier at Purchaser’s expense, F.O.B., Supplier’s Facility. All Tooling and Equipment shall be the property of
Purchaser and at all times hereunder shall remain the property of Purchaser. Supplier shall use the Tooling and Equipment solely for the purpose of manufacturing the Materials. Supplier shall not copy such Tooling and shall not manufacture the
Materials for any third party. All other materials required for the production, packaging and shipping of the Materials for Purchaser shall be supplied by Supplier, and the parties acknowledge that the cost of such materials is included in the
Materials Price set forth in Section 5.1 hereof. Although Purchaser shall retain ownership of the Tooling and Equipment, Supplier shall bear the risk of loss for the Tooling and Equipment commencing with its delivery to Supplier’s
manufacturing facility until returned to Purchaser. 
  

					
	DexCom Confidential	  	4	  	

 ******CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 
  

 (b) Supplier’s Acceptance of Tooling and Equipment. Supplier shall
receive the Tooling and Equipment from Purchaser and shall test such Tooling and Equipment in accordance with the testing instructions set forth in Exhibit A. Simultaneously with the provision of notice to Purchaser, Supplier shall
provide written notice of any defect or nonconformance, if any. 
 (c) Tooling and Equipment Labeling and
Protection. Supplier shall (i) label the Tooling and Equipment as the property of Purchaser, (ii) maintain at all times insurance with terms consistent with industry standards insuring the Tooling and Equipment against loss and
destruction and naming Purchaser as an additional insured (iii) keep the Tooling and Equipment free of any and all liens or encumbrances, (iv) allow Purchaser at its request to enter Supplier’s premises to inspect or take possession
of the Tooling and Equipment, and (v) execute and take such actions as may be requested by Purchaser, including the execution and filing of any financing statements, to identify Purchaser’s ownership and title in and to the Tooling and
Equipment. 
 (d) Right of Inspection. Upon reasonable notice during normal business hours, Purchaser shall have
the right to inspect Supplier’s manufacturing to determine and assess Supplier’s compliance with the provisions of this Section 4.1. 
 4.2 Manufacture of Materials. Supplier shall manufacture Materials in accordance with the Materials Specifications and all Applicable Laws, as then in effect, including without limitation all laws and regulations of such
territories applicable to the transportation, storage, use, handling and disposal of hazardous materials according to local, state and federal regulations. If new laws, rules or regulations become Applicable Laws, Supplier will make reasonable
efforts to comply and the parties shall negotiate in good faith an equitable price adjustment for the Materials to reflect an appropriate allocation of any increased costs actually borne by Supplier in complying with such Applicable Laws. Without
limiting the generality of the foregoing, Supplier shall (a) take all steps necessary to ensure that any Materials that may be produced by it pursuant to this Agreement shall be free of cross-contamination from any other manufacturing or
similar activities and (b) be responsible for validated cleaning and changeover procedures prior to manufacturing Materials hereunder. Each party shall promptly notify the other of any new instructions or specifications required by Applicable
Laws and shall confer with each other with respect to the best means to comply with such requirements. Upon request and at mutually agreeable times, Supplier will permit representatives of Purchaser to observe such manufacture and to have access to
any relevant records in connection with such manufacture. Upon Purchaser’s written request, Supplier shall supply Purchaser with copies of Supplier’s manufacturing records for the purposes of assuring Materials quality and compliance with
Supplier’s manufacturing procedures. Purchaser acknowledges that all copies of Supplier’s manufacturing records shall be protected under the confidentiality provisions of Article 11. Supplier represents and warrants to Purchaser that
it has and will maintain during the term of this Agreement all government permits, including without limitation health, safety and environmental permits, necessary for the conduct of the actions and procedures that it undertakes pursuant to this
Agreement. 
 4.3 Non-U.S. Legal Requirements. If Purchaser requires Materials to be manufactured in accordance with any rules
and regulations of Governmental Authorities outside the United States, Purchaser shall notify Supplier in writing of such requirements reasonably in advance of the date that such requirements must be implemented. Supplier shall provide Purchaser
with prompt written 

  

					
	DexCom Confidential	  	5	  	

 ******CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 
  

 
notice of whether it is able to, and will, comply with such additional requirements. The parties shall discuss a fair apportionment of any material increases
in the cost of manufacture of Materials that result from such additional requirements. Each party shall promptly notify the other of any new instructions or changes to Materials Specifications required by any Governmental Authority. The parties
shall confer with each other with respect to the best means to comply with such requirements. However, Supplier is not required to comply with foreign rules, unless agreed to in writing by both parties. 
 4.4 Quality Statement. Exhibit D attached hereto further details the quality assurance obligations of the parties with
respect to the Materials (the “Quality Statement”). Notwithstanding anything to the contrary in this Agreement or any other document or agreement, in the event of a conflict between, this Agreement and the Quality Statement,
this Agreement shall govern. 
 4.5 Regulatory Support. Purchaser and Supplier shall use commercially reasonable efforts to
respond to all reasonable requests for information from, and in making all required filings with, federal, state or local governmental or regulatory authorities having jurisdiction to make such requests or require such filings. Supplier shall obtain
and comply with all licenses, consents, permits and regulations which may from time to time be required by appropriate governmental and regulatory authorities with respect to the performance of its obligations hereunder. 
 4.6 QA Audits. Upon Purchaser’s reasonable written advance request to Supplier, Purchaser shall have the right to have representatives
visit the Supplier Facility during normal business hours to review Supplier’s manufacturing operations and assess its compliance with quality assurance standards and to discuss any related issues with Supplier’s manufacturing and
management personnel. 
 4.7 Change in Manufacturing Process. Supplier shall obtain Purchaser’s prior written approval,
which shall not be unreasonably withheld, before Supplier implements any change in the Materials, equipment, processes or procedures used to manufacture Materials. Supplier shall disclose all such proposed changes in such manufacturing Materials,
equipment, processes or procedures to Purchaser at a level sufficient to allow Purchaser to reasonably evaluate the effect of such changes. 
 4.8 Failed Batch. Supplier shall investigate, and cooperate fully with Purchaser in investigating, any batch of Materials that fails to meet Materials Specifications or the requirements of any U.S. Governmental Authority with
jurisdiction over the manufacture of Materials. Supplier shall keep Purchaser informed of the status of any investigation and, upon completion of the investigation, shall provide Purchaser with a final written report describing the cause of the
failure and summarizing the results of the investigation. 
 4.9 Documentation. Supplier shall keep complete, accurate and
authentic accounts, notes, data and records of the work performed under this Agreement adequate to comply with all Applicable Laws. Supplier shall maintain complete and adequate records pertaining to the methods and facilities used for the
manufacture, processing, testing, packing, labeling of the Materials in accordance with the Applicable Laws. 
  

					
	DexCom Confidential	  	6	  	

 ******CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 
  

	5.	PRICES AND PAYMENT. 

 5.1 Price. For
all Materials supplied to Purchaser pursuant to this Agreement, Purchaser shall pay to Supplier the Materials Price set forth in Exhibit B hereto, subject to adjustment in accordance with Section 5.2 hereof. The parties
acknowledge and agree that Supplier shall be responsible for all payments to Third Parties for all inputs purchased from, or other product or services provided by Third Parties in connection with the manufacture and packaging of Materials.

 5.2 Price Increases. The Materials Price will be adjusted annually commencing on the [******] anniversary of the First
Shipment of Materials. The initial adjustment shall be based on the percentage change in the Producer Price Index, published by the United States Department of Labor, Bureau of Labor Statistics (“PPI”), or cost changes
imposed by any raw material components, fully burdened labor costs and testing services over and above the PPI. Supplier needs to provide the supporting documentation to Purchaser to justify the price increase above the PPI. Thereafter, the
Materials Price shall be adjusted on [******] in an amount equal to the percentage change in the PPI for the prior [******] month period or based on cost increases as provided above. 
 5.3 Invoices. Supplier shall invoice Purchaser for the aggregate Materials Price of each shipment of Materials at the time of such
shipment. 
 5.4 Payment. Each invoice shall be paid to Supplier in United States Dollars not later than [******]days following
the later of (i) the receipt of the applicable invoice or (ii) the receipt of the relevant batch of Materials at its destination, unless such shipment of Materials is properly rejected under the provisions of Section 6.4. Any invoiced
amount which is not paid within [******]days of its due date shall be assessed a late payment fee at the rate of [******] per month or the maximum rate permitted by applicable law with respect to such obligations, whichever is less, unless subject
to a valid dispute. 
  

	6.	DELIVERY AND ACCEPTANCE. 

 6.1 Reserved. 

 6.2 Delivery. Unless otherwise agreed by the parties in writing, all shipments of Materials shall be shipped F.O.B. the
Supplier Facility. Supplier will package and ship Materials in accordance with the requirements of Purchaser as agreed to by Supplier. 
 6.3 Timely Delivery. Supplier agrees to use its commercially reasonable efforts to ensure that Materials ordered by Purchaser hereunder shall be delivered on the scheduled delivery dates set forth in the relevant purchase
orders. 
 6.4 Acceptance and Rejection. 
 (a) Purchaser may reject any batch delivery which does not conform with the Materials Specifications or with applicable documentation and process requirements. Any such notice of rejection shall be in writing and
shall indicate the reasons for such rejection. 
 (b) Reserved. 
  

					
	DexCom Confidential	  	7	  	

 ******CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 
  

 (c) In order to reject delivery of a full batch of Materials, Purchaser must
give written notice to Supplier of Purchaser’s rejection of any delivery within [******] after receipt of such delivery. If no such notice of rejection is timely received, Purchaser shall be deemed to have accepted such delivery of Materials
within [******]of delivery of the batch. Once Purchaser accepts a batch of Materials, Purchaser shall have no recourse against Supplier if the product is subsequently deemed unsuitable for use for any reason, except for Latent Defects or as provided
in Article 10 below. 
 (d) After notice of rejection is given, Purchaser shall cooperate with Supplier in
determining whether rejection is necessary or justified. Supplier will evaluate process issues and other reasons for such non-compliance. Supplier shall notify Purchaser as promptly as reasonably possible whether it accepts Purchaser’s basis
for any rejection. If Supplier in good faith disagrees with Purchaser’s determination that certain Materials does not meet the Materials Specifications, such Materials shall be submitted to a mutually acceptable Third Party laboratory. Such
Third Party laboratory shall determine whether such Materials meets the Materials Specifications and the parties agree that such laboratory’s determination shall be final and determinative. The party against whom the Third Party tester rules
shall bear all costs of the Third Party testing. Whether or not Supplier accepts Purchaser’s basis for rejection, promptly on receipt of a notice of rejection of a full batch of Materials, Supplier shall use reasonable efforts at
Purchaser’s request to replace such rejected Materials. If the Third Party tester rules that the batch meets Materials Specifications, Purchaser shall purchase that batch and any replacement batch at the agreed-upon price, irrespective of
whether Supplier has already replaced it. 
 (e) Purchaser may not destroy any batch of Materials until it receives
written notification from Supplier that Supplier does not dispute that the batch fails to meet Materials Specifications and that Supplier does not request return of the Materials. Upon authorization from Supplier to do so, Purchaser shall destroy
the Materials received in the rejected delivery promptly at Supplier’s cost and provide Supplier with certification of such destruction. Purchaser shall, upon receipt of Supplier’s request for return, promptly return said Materials or
quality control sample to Supplier, at Supplier’s cost. 
  

	7.	INTELLECTUAL PROPERTY RIGHTS. 

 7.1 No
Implied License. Except as expressly provided herein, no party hereto shall be deemed by this Agreement to have been granted any license or other rights to patent rights existing as of the date hereof, or know-how relating to compounds,
formulations, products or processes which are owned, licensed or controlled by another party. 
 7.2 Ownership of Certain
Inventions. With respect to any ideas, discoveries, inventions, improvements, innovations and the like (whether or not patentable) developed by Supplier or its employees or agents relating to the Materials (each an “Invention”
and collectively, the “Inventions”), the parties agree that such Inventions shall remain the property of Supplier, and that Purchaser shall have, and Supplier hereby grants to Purchaser, a worldwide, royalty-free,
irrevocable, license, which license shall be exclusive to Supplier in the field of continuous glucose monitoring products and non-exclusive for any other applications, without right to sublicense (other than in connection with the sale of Products),
under Supplier’s patent and other intellectual property rights in any and all such Inventions only for use in combination with Purchaser’s Products for the Term of this Agreement. 
  

					
	DexCom Confidential	  	8	  	

 ******CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 
  

	8.	REGULATORY. 

 8.1 Adverse Event Reporting;
Materials Complaints. Purchaser shall be responsible for all reporting to regulatory authorities Adverse Events to the extent required based on the use of Materials supplied by Supplier hereunder in Purchaser’s Products. Purchaser shall
advise Supplier promptly after Purchaser becomes aware of any such Adverse Events. If Supplier becomes aware of any Adverse Events associated with the use of such Materials, it shall report all information in its possession regarding such event to
Purchaser as soon as practicable after becoming aware of such information, and shall cooperate with Purchaser as necessary to report such event under Applicable Laws. Purchaser shall also notify Supplier as soon as practicable of any complaints of
which it becomes aware regarding problems with Materials other than those associated with Adverse Events, and Purchaser shall meet and confer with Supplier with respect to its responses to such complaints and whether any remedial actions by Supplier
are indicated by the pattern of complaints. 
 8.2 Regulatory Compliance. Supplier shall comply with all regulatory
requirements with respect to Materials imposed by Applicable Law upon Supplier as the manufacturer of the Materials. If new regulatory requirements become Applicable Laws, Supplier will make reasonable efforts to comply and the parties shall
negotiate in good faith an equitable price adjustment for the Materials to reflect an appropriate allocation of any increased costs actually borne by Supplier in complying with such Applicable Laws. Purchaser shall comply with all regulatory
requirements with respect to Materials that are imposed by Applicable Law upon Purchaser as the holder of Regulatory Approvals. Supplier shall, on a timely basis, provide Purchaser with information in Supplier’s possession relevant to its role
as the manufacturer of the Materials, that is reasonably necessary for and relevant to Purchaser’s obligations hereunder in complying with such regulatory requirements as required by Applicable Laws. 
 8.3 Cooperation. Supplier will provide to Purchaser such documentation, data and other information relating to Materials as Purchaser may
require for submission to Governmental Authorities or as required by Applicable Laws. Supplier shall also provide, upon request by Purchaser, reasonably necessary information concerning its production processes and quality control procedures with
respect to Materials. 
 8.4 Recalls. In the event Purchaser shall be required or requested by any Governmental Authority (or
shall voluntarily decide in good faith) to recall a Product, Purchaser shall coordinate such recall. If a recall arises primarily out of Supplier’s negligence, willful misconduct or breach of this Agreement, and does not result from
Purchaser’s negligence, willful misconduct or breach of this Agreement, then Supplier shall reimburse Purchaser for (i) the purchase price paid by Purchaser to Supplier for such recalled Materials, and (ii) all of Purchaser’s
other direct reasonable costs and expenses actually incurred by Purchaser in connection with the recall including, but not limited to, costs of retrieving Materials already delivered to customers, costs and expenses Purchaser is required to pay for
notification, shipping and handling charges, and all other costs reasonably related to the recall, not exceeding $[*****] in total. If a recall is due to any reason other than one that is primarily attributable either to Supplier’s negligence,
willful misconduct or breach of this Agreement, or out of Supplier’s negligence, willful misconduct or breach of this Agreement, Purchaser shall pay the costs and expenses of the recall. 
  

					
	DexCom Confidential	  	9	  	

 ******CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 
  

 8.5 Regulatory Inspections. Supplier agrees to inform Purchaser within two
(2) business days of any regulatory inquiry, communication or inspection, which directly or indirectly relates to the manufacture of any of the Materials. In the event Supplier receives a notice of inspection or an inspection visit by any
Governmental Authority which involves Materials or could impact Supplier’s ability to produce Materials, Supplier shall notify Purchaser within twenty four (24) hours. Purchaser, at its option, shall have the right to have its
representatives present at any such inspection by a Government Authority, if the inspection pertains to Purchaser Materials. In the event there are written observations (or any other written communication) by a Governmental Authority that involve
Materials or could impact Supplier’s ability to produce Materials, or any proposed written response by Supplier to any such inspection, Purchaser shall be informed within two business days and be provided with copies of all documentation within
two (2) business days, and shall have a reasonable opportunity to review and comment on the proposed response. If Purchaser elects to provide input to the response, such input shall be provided by Purchaser as promptly as possible and Supplier
shall in good faith incorporate such input into the response. 
 8.6 Incidents or Accidents. Supplier shall immediately notify
Purchaser in writing of any incident or accident experienced by such party that such party in its reasonable judgment believes may affect the quality of Materials that Supplier is obligated to deliver hereunder or its ability to meet delivery date
obligations hereunder. Such incident or accident shall be immediately investigated by Supplier, and Supplier shall provide a written report within five (5) working days of the results of the investigation of such incidence or accident to
Purchaser. 
  

	9.	REPRESENTATIONS AND WARRANTIES. 

 9.1
Mutual Representations and Warranties. Each party hereby represents and warrants to the other party as follows: 
 (a) Existence and Power. Such party (i) is duly organized, validly existing and in good standing under the laws of the state or other jurisdiction in which it is organized; (ii) has the power and authority and the
legal right to own and operate its property and assets, to lease the property and assets it operates under lease, and to carry on its business as it is now being conducted; and (iii) is in compliance with all requirements of Applicable Laws to
the extent required by this Agreement, except to the extent that any noncompliance would not have a material adverse affect on such party’s ability to perform its obligations under the Agreement. 
 (b) Authorization and Enforcement of Obligations. Such party (i) has the power and authority and the legal right to
enter into this Agreement and to perform its obligations hereunder and (ii) has taken all necessary action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement
has been duly executed and delivered on behalf of such party, and constitutes a legal, valid, binding obligation, enforceable against such party in accordance with its terms. 
 (c) No Consents. All necessary consents, approvals and authorizations of all Governmental Authorities and other persons
required to be obtained by such party in connection with this Agreement have been obtained, except for those which cannot be obtained prior to the regulatory approval of the Materials. 
  

					
	DexCom Confidential	  	10	  	

 ******CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 
  

 (d) No Conflict. The execution and delivery of this Agreement and the
performance of such party’s obligations hereunder (i) do not conflict with or violate any requirement of Applicable Laws or regulations or any material contractual obligation of such party and (ii) do not materially conflict with, or
constitute a material default or require any consent under, any material contractual obligation of such party. Supplier shall in no event enter into any agreement or arrangement with any Third Party that would prevent or in any way interfere with
its obligations pursuant to this Agreement. 
 9.2 Supplier Representations and Warranties. Supplier represents and warrants to
Purchaser as follows: (a) the Materials shall be manufactured in compliance with relevant Approval Applications filed by Purchaser and all other Applicable Laws; (b) shall conform to the Materials Specifications in effect at the time of
delivery; (c) shall conform to the Certificates of Analysis supplied with the shipment of the Materials; (d) shall be packaged and shipped in accordance with the Materials Specifications in effect at the time of delivery and the terms of
this Agreement; (e) to the best of Supplier’s knowledge, the Materials do not infringe any Third Party patents or other intellectual property rights; and (f) shall be free and clear of any lien or encumbrance. 
 9.3 Warranty Disclaimers and Limitations. EXCEPT AS SET FORTH IN SECTIONS 9.1 AND 9.2, SUPPLIER MAKES NO WARRANTIES WITH RESPECT TO PRODUCT
SUPPLIED TO PURCHASER, EXPRESS OR IMPLIED, AND SPECIFICALLY, WITHOUT LIMITATION, SUPPLIER DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND AGAINST INFRINGEMENT. 
 9.4 Limitation of Liability. IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES
INCURRED BY THE OTHER PARTY, OR ANY PUNITIVE OR EXEMPLARY DAMAGES, WHETHER IN CONTRACT OR TORT OR BASED ON A WARRANTY, EVEN IF THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
  

	10.	INDEMNIFICATION. 

 10.1 Supplier
Indemnification. Subject to the limitations in Section 9.4, Supplier, together with its Affiliates, shall indemnify, defend and hold Purchaser, its Affiliates and their respective directors, officers, employees, consultants and sublicensees
other than Supplier (each, a “Purchaser Indemnitee”) harmless from and against any and all costs, losses, claims, liabilities, fines, penalties, damages and expenses, court costs, and reasonable fees and disbursements of
counsel, consultants and expert witnesses (collectively, “Damages”) incurred or suffered by a Purchaser Indemnitee as a result of Third Party claims, actions or proceedings arising from bodily injury or property damage
(collectively, “Third Party Claims”) to the extent such Third Party Claims are a consequence of (i) the breach of any representation or warranty or other provision of this Agreement by Supplier, or (ii) the
negligence or willful misconduct of Supplier or its Affiliates, in each case except to the extent that such Damages result from the willful misconduct or negligent acts or omissions of a Purchaser Indemnitee or breach of this Agreement. 

 

					
	DexCom Confidential	  	11	  	

 ******CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 
  

 10.2 Purchaser Indemnification. Purchaser shall indemnify, defend and hold Supplier,
its Affiliates, and their respective directors, officers, employees and consultants (each, a “Supplier Indemnitee”) harmless from and against any and all Damages incurred by a Supplier Indemnitee as a result of Third Party
Claims to the extent such Third Party Claims are a consequence of (i) the breach of any representation or warranty or other provision of this Agreement by Purchaser; (ii) the negligence or willful misconduct of Purchaser, its Affiliates or
Third Party sublicensees; or (iii) arising from any defect or deficiency in any Product, in each case except to the extent that such Damages result from any circumstance as to which Supplier has an indemnity obligation under Section 10.2.

 10.3 Notice and Assistance. If a party or any of its directors, officers, employees, consultants, Affiliates
or sublicensees has a right to be indemnified under this Article 10 (each, an “Indemnified Party”), (i) the Indemnified Party shall give prompt notice of such Third Party Claim to the party from whom indemnification
is sought hereunder (the “Indemnifying Party”) and (ii) the Indemnifying Party will have the first right to defend any Third Party Claims for which it is required to Indemnify the Indemnified Party, with the cooperation and at the
expense of such Indemnifying Party, provided that it will not settle any such Third Party Claim without the prior written consent of the Indemnified Party, which consent shall not be unreasonably withheld. If the Indemnifying Party is defending a
Third Party Claim, the Indemnified Party shall have the right to be present in person or through counsel at substantive legal proceedings. In the event that the parties cannot agree as to the application of Sections 10.1 or 10.2 as to any Damages or
Third Party Claim, the parties may conduct separate defenses of such claim. Each party further reserves the right to claim indemnity from the other in accordance with Sections 10.1 or 10.2 upon resolution of the underlying claim. 
 10.4 Insurance. Each party shall, throughout the term of this Agreement, obtain and maintain, at its own cost and expense, from a reputable
insurance company, comprehensive product liability insurance in reasonable and adequate amounts. Purchaser agrees to name Supplier as additional insured on its policy. The amounts of insurance coverage required hereunder shall not be construed to
create a limit on any party’s liability with respect to its indemnification obligations hereunder. Each party shall furnish the other party a certificate of insurance evidencing such insurance upon request and shall provide the other party with
written notice at least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance. Each party’s obligation to maintain such insurance shall continue until five (5) years after termination of this
Agreement. 
  

	11.	CONFIDENTIALITY. 

 11.1 Treatment of
Confidential Information. The parties agree that during the term of this Agreement, and for a period of [******] years after this Agreement expires or terminates, a party receiving Confidential Information of the other party will
(i) maintain in confidence such Confidential Information to the same extent such party maintains its own proprietary information of similar kind and value (but at a minimum each party shall use commercially reasonable efforts to maintain
Confidential Information in confidence), (ii) not disclose such Confidential Information to any Third Party without prior written consent of the disclosing party, and (iii) not use such Confidential Information for any purpose except those
permitted by this Agreement. A party shall have no such obligation with respect to any portion of such Confidential Information which: 
 (a) is publicly disclosed by the disclosing party, either before or after it becomes known to the receiving party; 
  

					
	DexCom Confidential	  	12	  	

 ******CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 
  

 (b) was known to the receiving party, without obligation to keep it
confidential, prior to when it was received from the disclosing party; 
 (c) is subsequently disclosed to the
receiving party by a Third Party lawfully in possession thereof without obligation to keep it confidential; 
 (d) has
been published by a Third Party; or 
 (e) has been independently developed by the receiving party without the aid,
application or use of Confidential Information. 
 11.2 Permitted Disclosures. Notwithstanding any other provision of this
Agreement, Purchaser may disclose Confidential Information belonging to Supplier to the extent such disclosure is reasonably necessary for regulatory filings, prosecuting or defending litigation, complying with applicable governmental regulations,
conducting pre-clinical or clinical trials by or for Purchaser and marketing and selling Product. If Purchaser is so required to disclose any Confidential Information belonging to Supplier to a Government Authority or to any other Third Party,
Purchaser shall immediately notify Supplier in writing of all details of the required disclosure and permit Supplier to intervene to oppose, limit or condition such disclosure prior to Purchaser making any disclosure and Purchaser shall make any
such disclosure ultimately required in the most restrictive fashion consistent with the requirement as determined by a court or regulatory agency of competent jurisdiction. Except as otherwise agreed to herein, if Supplier is required by law to
disclose any Confidential Information of Purchaser to a Government Authority or to any other Third Party, Supplier shall immediately notify Purchaser in writing of all details of the required disclosure and permit Purchaser to intervene to oppose,
limit or condition such disclosure prior to Supplier making any disclosure, and Supplier shall make any such disclosure ultimately required in the most restrictive fashion consistent with the requirement as determined by a court or regulatory agency
of competent jurisdiction. 
 11.3 Injunctive Relief. The parties expressly acknowledge and agree that any breach or threatened
breach of this Article 11 may cause immediate and irreparable harm to the disclosing party that may not be adequately compensated by damages. Each party therefore agrees that in the event of such breach or threatened breach and in addition to
any remedies available at law, the disclosing party shall have the right to seek equitable and injunctive relief, without bond, in connection with such a breach or threatened breach. 
  

	12.	TERM AND TERMINATION. 

 12.1 Term. The
term of this Agreement shall commence on the Effective Date and shall continue until for a period of three (3) years (“Initial Term”) unless earlier terminated in accordance with this Article 12. Following the
Initial Term, the term of this Agreement may be extended for an additional [******] solely at Purchaser’s option (“Purchaser Renewal Option”). Following the Purchaser Renewal Option, this Agreement shall renew for
successive [******] terms unless terminated by either party by providing the other party with not less than 180 days prior written notice. 
  

					
	DexCom Confidential	  	13	  	

 ******CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 
  

 12.2 Termination for Material Breach. Either party may terminate this Agreement upon written
notice to the other party if the other party commits any material breach of this Agreement which the breaching party fails to cure within sixty (60) days following written notice from the non-breaching party specifying such breach. 

12.3 Surviving Obligations. Termination of this Agreement shall not (a) affect any other rights of either party which may have accrued up
to the date of such termination or (b) preclude either party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement. The provisions of Sections 4.5, 4.9 and 5.4 and
Articles 7, 8, 9, 10, 11, 12 and 13 shall survive the termination of this Agreement. 
  

	13.	MISCELLANEOUS. 

 13.1 Governing Law.
This Agreement shall be governed by and construed in accordance with the laws of the State of California, without regard to conflicts of laws provisions. 
 13.2 Assignment. Except as otherwise provided herein, neither this Agreement nor any interest hereunder will be assignable in whole or in part by a party without the prior written consent of the other,
provided however, that Purchaser or Supplier may assign this Agreement to any of its Affiliates or to any successor by merger or sale of substantially all of its business or assets to which this Agreement relates. This Agreement shall be
binding upon the successors and permitted assigns of the parties and the name of a party appearing herein will be deemed to include the names of such party’s successors and permitted assigns to the extent necessary to carry out the intent of
this Agreement. Any assignment which is not in accordance with this Section 13.2 shall be void. 
 13.3 Arbitration. Any
controversy arising under or related to this Agreement, and any disputed claim by any party against another under this Agreement, excluding any dispute relating to patent validity or infringement arising under this Agreement, shall be settled by
arbitration in accordance with the then existing Commercial Arbitration Rules of the American Arbitration Association (the “Rules”). Upon request by a party, arbitration will be by a panel of three arbitrators within
thirty (30) days of such arbitration request. One arbitrator will be selected by Purchaser, one arbitrator will be selected by Supplier, and the third arbitrator will be selected by mutual agreement of the two arbitrators selected by the
parties. In any such arbitration, the parties shall select a panel with relevant experience in the medical device industry. Judgment upon the award rendered by the panel shall be final and nonappealable and may be entered in any court having
jurisdiction thereof. In order to conduct discovery, and in addition to the discovery provisions provided under the Rules, the parties expressly incorporate into any arbitration occurring under this Agreement the discovery rules provided for in the
Federal Rules of Civil Procedure of the United States of America. Any arbitration shall be held in San Diego, California, unless the parties hereto mutually agree in writing to another place. Notwithstanding the foregoing, nothing in this provision
shall be construed to bar a party from seeking interim equitable relief in order to preserve the status quo or prevent irreparable harm. 
  

					
	DexCom Confidential	  	14	  	

 ******CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 
  

 13.4 Notices. All notices required or
permitted to be given under this Agreement shall be in writing and shall be sent by registered or certified mail or a reputable courier service, addressed to the signatory to whom such notice is required or permitted to be given or transmitted by
facsimile to the number indicated below. All notices shall be deemed to have been given in the case of mailing on the fifth (5th) day following
the date of mailing, as postmarked at the point of mailing, or in the case of delivery by courier on the date of delivery, and in the case of facsimile transmission on the first day following the date of transmission. 
 All notices to Purchaser shall be addressed as follows: 
 DexCom, Inc. 
 6340 Sequence Drive 
 San Diego, California 92121 
 Telephone:
858-200-0200 
 Facsimile: 858-875-5324 
 Attention: Legal Department 
 All notices to Supplier shall be addressed as follows: 
 The Polymer Technology Group 
 2810 7th Street

 Berkeley, CA 94710 
 Telephone:
(510) 841-8800 
 Facsimile: (510) 841-7800 
 Attention: Robert Ward 
 13.5 Amendment. No amendment, modification or waiver of any terms or
conditions hereof shall be effective unless made in writing and signed by a duly authorized officer of each party. 
 13.6 Disclaimer of
Agency. Neither party is, or will be deemed to be, the legal representative or agent of the other party, nor shall either party have the right or authority to assume, create, or incur any Third Party liability or obligation of any kind, express
or implied, against or in the name of or on behalf of the other except as expressly set forth in this Agreement. 
 13.7 Non-Waiver.
The failure of a party in any one or more instances to insist upon strict performance of any of the terms and conditions of this Agreement shall not constitute a waiver or relinquishment, to any extent, of the right to assert or rely upon any such
terms or conditions on any future occasion. 
 13.8 Severability. If a court of competent jurisdiction or arbitrator declares any
provision of this Agreement invalid or unenforceable, or if any government or other agency having jurisdiction over any party deems any provision to be contrary to any laws, then that provision shall be severed and the remainder of the Agreement
shall continue in full force and effect. To the extent possible, the parties shall revise such invalidated provision in a manner that will render such provision valid without impairing the parties’ original intent. 
  

					
	DexCom Confidential	  	15	  	

 ******CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 
  

 13.9 Entire Agreement. This Agreement (including all exhibits hereto) embodies the entire,
final and complete agreement and understanding between the parties and replaces and supersedes all prior discussions and agreements between them with respect to its subject matter. 
 13.10 Headings. The headings contained in this Agreement are inserted for reference only and shall not be deemed a part of the text hereof.

 13.11 Counterparts. This Agreement may be executed in multiple counterparts (which may be delivered by facsimile), each of which
shall be an original and all of which shall constitute together the same document. 
  

					
	DexCom Confidential	  	16	  	

 ******CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED
WITH THE SECURITIES EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 
  

 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the date first
set forth above. 
  

									
	 DEXCOM, INC.
 a Delaware
corporation
	 		 	 PTG MEDICAL, LLC
 a California
limited liability company

					
	By:	 	/s/ Jess Roper	 		 	By:	 	/s/ Terry Robertson
	Name:	 	Jess Roper	 		 	Name:	 	Terry Robertson
	Its:	 	Chief Financial Officer	 		 	Its:	 	Chief Operating Officer

  

					
	DexCom Confidential	  	17	  	

 EXHIBIT A 
 Tooling and Equipment Provided by Purchaser 
 [******] 
  

					
	DexCom Confidential	  	A	  	

 EXHIBIT B 
 Materials Pricing 
 [******]per gallon of Materials 
  

					
	DexCom Confidential	  	B	  	

 EXHIBIT C 
 Materials Specifications 
 [*****] 
  

							
	 Characteristic
	  	Test Method	  	Specification	  	Result
				
	 [*****]
	  	[*****]	  	[*****]	  	
				
	 [*****]
	  	[*****]	  	[*****]	  	
				
	 [*****]
	  	[*****]	  	[*****]	  	
				
	 [*****]
	  	[*****]	  	[*****]	  	
				
	 [*****]
	  	[*****]	  	[*****]	  	
				
	 [*****]
	  	[*****]	  	[*****]	  	
				
	 [*****]
	  	[*****]	  	[*****]	  	
				
	 [*****]
	  	[*****]	  	[*****]	  	

 [*****] 
  

							
	 Characteristic
	  	Test Method	  	Specification	  	Result
				
	 [*****]
	  	[*****]	  	[*****]	  	
				
	 [*****]
	  	[*****]	  	[*****]	  	
				
	 [*****]
	  	[*****]	  	[*****]	  	
				
	 [*****]
	  	[*****]	  	[*****]	  	
				
	 [*****]
	  	[*****]	  	[*****]	  	
				
	 [*****]
	  	[*****]	  	[*****]	  	
				
	 [*****]
	  	[*****]	  	[*****]	  	
				
	 [*****]
	  	[*****]	  	[*****]	  	

  

					
	DexCom Confidential	  	C	  	

 EXHIBIT D 
 Quality Statement 
 [******] 
  

					
	DexCom Confidential	  	DJoint Venture Agreement

 Exhibit 10.1 
  
  
  
 JOINT VENTURE AGREEMENT 
 between

 DANONE DAIRY ASIA 
 and 
 WEIGHT WATCHERS ASIA HOLDINGS LTD. 
 for 
 the establishment of 
 WEIGHT WATCHERS DANONE CHINA LIMITED 
  
  
 Dated as of February 5,
2008 
  
  
  
  
  

 Table of Contents 
  

					
	 	  	 	  	Page
			
	 SECTION 1
	  	DEFINITIONS	  	1
			
	 SECTION 2
	  	ESTABLISHMENT OF THE COMPANY AND WFOES	  	12
			
	 SECTION 3
	  	SCOPE OF BUSINESS OPERATIONS	  	12
			
	 SECTION 4
	  	SHARE CAPITAL AND INCREASE OF SHARE CAPITAL	  	13
			
	 SECTION 5
	  	TRANSFER OF INTEREST	  	15
			
	 SECTION 6
	  	CONDITIONS FOR COOPERATION AND RESPONSIBILITIES OF THE PARTIES	  	20
			
	 SECTION 7
	  	CONFIDENTIAL INFORMATION, PUBLICITY AND INTELLECTUAL PROPERTY RIGHTS	  	23
			
	 SECTION 8
	  	CORPORATE GOVERNANCE	  	25
			
	 SECTION 9
	  	MANAGEMENT OF THE COMPANY	  	33
			
	 SECTION 10
	  	FINANCIAL, ACCOUNTING AND AUDITING SYSTEM	  	35
			
	 SECTION 11
	  	PROFIT DISTRIBUTIONS	  	39
			
	 SECTION 12
	  	BUDGETS AND BUSINESS PLAN	  	39
			
	 SECTION 13
	  	TERM, TERMINATION AND LIQUIDATION	  	41
			
	 SECTION 14
	  	TERMINATION PURCHASE RIGHT	  	42
			
	 SECTION 15
	  	MILESTONES	  	43
			
	 SECTION 16
	  	LIABILITY FOR BREACH OF CONTRACT	  	44
			
	 SECTION 17
	  	GOVERNING LAW AND DISPUTE RESOLUTION	  	44
			
	 SECTION 18
	  	REPRESENTATIONS AND WARRANTIES	  	45
			
	 SECTION 19
	  	EFFECTIVENESS OF THE CONTRACT AND MISCELLANEOUS	  	47
			
	 APPENDIX 1
	  	CHARTER DOCUMENTS	  	
			
	 APPENDIX 2
	  	FORM OF SERVICES AGREEMENT	  	
			
	 APPENDIX 3
	  	DEED OF ADHERENCE	  	
			
	 APPENDIX 4
	  	FORM OF LICENSE AGREEMENT	  	

  

 (i) 

					
	 APPENDIX 5
	  	FORM OF CONFIDENTIALITY AGREEMENT	  	
			
	 APPENDIX 6
	  	LIST OF SHANGHAI WFOE APPROVALS	  	

  

 (ii) 

 THIS JOINT VENTURE AGREEMENT (this “Agreement”) is made as of the 5th day of February 2008

 BETWEEN: 
  

	(1)	Danone Dairy Asia, a company organized and existing under the laws of France, with its offices at 17 boulevard Haussmann, 75009 Paris, France (“DAP”); and

  

	(2)	Weight Watchers Asia Holdings Ltd., a company organized and existing under the laws of the Cayman Islands, with its offices at Paget-Brown Trust Company Ltd., Boundary Hall, Cricket
Square, P.O. Box 1111, Grand Cayman KY1-1102, Cayman Islands (“WTW”). 

 Each of DAP and WTW is referred to
hereinafter as a “Party” and collectively as the “Parties.” 
 RECITALS 
  

	(A)	DAP is a wholly-owned subsidiary of Groupe Danone (“GD”), a company organized and existing under the laws of France and engaged in the business of manufacturing and
distributing food and beverage products. 

  

	(B)	WTW is a wholly-owned subsidiary of Weight Watchers International, Inc. (“WWI”), a corporation organized and existing under the laws of Virginia, the United States
of America, and engaged in the business of weight management. 

  

	(C)	The Parties intend to combine their strengths by establishing and investing in a joint venture company (the “Company”) in Hong Kong that will in turn establish
various Subsidiaries (as defined below), including one or more wholly foreign-owned enterprises in the People’s Republic of China (each, a “WFOE”, collectively, the “WFOEs”), the initial one shall be
established in Shanghai (the “Shanghai WFOE”) to engage in the Licensed Business (as defined below). 

  

	(D)	The Parties wish to provide for certain matters relating to the management and operation of the Company and the WFOEs. 

 AGREEMENT: 
 SECTION 1 
 DEFINITIONS 
  

	1.1	Definitions. In this Agreement, unless the context otherwise requires, the following terms shall have the following meanings: 

 “Adjusted Group EBITDA” means the greater of (a) 11.5 times Group EBITDA or (b) 0, determined on a consolidated basis for the
Applicable Period in accordance with US GAAP. 

 “Adjusted Group Revenue” means 3.5 times the gross revenue of the Group on a
consolidated basis for the Applicable Period and determined in accordance with US GAAP. 
 “Affiliate” of a Person (the
“Subject Person”) means any other Person directly or indirectly Controlling, Controlled by, or under common Control with, the Subject Person; provided, however, (i) the Company and its Subsidiaries shall not be
deemed Affiliates of WWI, WTW, DAP or GD (ii) WTW, WWI, GD and DAP shall not be deemed Affiliates of each other, and (iii) Artal and Artal’s Affiliates, other than WWI or subsidiaries of WWI, shall not be deemed Affiliates of WWI or
WTW. 
 “Applicable Buyout Price” means an amount equal to the product of (a) the Buyout Price and (b) a fraction,
the numerator of which shall be the number of Shares held by the Non-Terminating Party and the denominator of which shall be the total number of Shares outstanding. 
 “Applicable Period” means the 12-month period ending on the last day of the last full calendar month preceding the date of termination of this Agreement. 
 “Approved Lines” has the meaning specified in the License Agreement. 
 “Artal” means Artal Group S.A., a Luxembourg company and the indirect parent of WTW. 
 “Arbitration Rules” means the Arbitration Rules of the United Nations Commission and International Trade Law. 
 “Board” means the board of directors of the Company. 
 “Books” means the records and books of account of the Company and the WFOEs (on a consolidated basis) (a) in which complete entries have been made in accordance with US GAAP and IFRS,
(b) for which all transactions required to be reflected by US GAAP and IFRS have been reflected and (c) for which accurate and complete records of the material properties and assets of the Company and the WFOEs have been kept in
accordance with US GAAP and IFRS. 
 “Business Day” means any day other than a Saturday, Sunday or other day on which
commercial banks in PRC, the State of New York of the U.S. or Hong Kong are required or authorized by Law or executive order to be closed. 
 “Business License” means the business license of each WFOE issued by SAIC. 
 “Buyout Price” means
an amount equal to the greater of (a) the amount equal to (i) the quotient of (1) sum of the Adjusted Group Revenue and the Adjusted Group EBITDA and (2) 2 minus (ii) the Net Indebtedness as of the date of termination of
this Agreement and (b) the Group Net Asset Value. 
  

 2 

 “Charter Documents” of the Company means the memorandum and articles of association of
the Company to be adopted by the Company on or prior to the Company Establishment Date, and in the form attached hereto as Appendix 1. 
 “CEO” of the Company means the Chief Executive Officer of the Company, who shall be the most senior executive manager of the Company. 
 “Company Establishment Date” means the date in which both DAP and WTW subscribe their Shares of the Company in accordance with Section 4 of this Agreement. 
 “Competitor” means: 
  

	 	(i)	with respect to WTW: Ao Quqing, Atkins, Curves, eDiets, Fernwood Women’s Health Clubs, Glaxo Smith Kline (Alli), GNC, Great Impression Brand Weight Reducing Tea, Herbalife,
Jenny Craig, Kancura Weight Reducing Tea, Lean Cuisine, Marie France, Mermaid Fitness, NutriSystem, QuMei, Roche Products (Weight Awareness/Xenical), Sanofi-Aventis (Accomplia), Sau San Tong, Scent Hill, Shu Yikang Shake Fat Appliance, Slimfast,
South Beach Diet, Slimming World, Sunrana Slimming Compound, Tesco, Tony Ferguson Weight Loss Program and VT, and their respective Affiliates (including, without limitation, any parent organizations such as Nestle in the case of Jenny Craig or
Unilever in the case of Slimfast); and 

  

	 	(ii)	with respect to GD: PepsiCo Inc., The Coca Cola Company, Nestle SA, Kraft Foods Inc., Unilever and their respective Affiliates. 

 “Confidential Information” means (a) all information disclosed to a Party, its subsidiaries, employees, directors, officers,
Affiliates, consultants, subcontractors, representatives or advisors (the “Recipient”) by the other Party, the Company, or in the case where the Recipient is DAP, WWI (in addition to the other Party and the Company), or in the case
where the Recipient is WWI, GD (in addition to the other Party and the Company), or any of their employees, directors, officers, Affiliates, consultants, subcontractors, representatives or advisors (the “Disclosing Party”),
including all information concerning the Disclosing Party’s or any of its Affiliates’ businesses, finances, designs, advertising, marketing, sales, plans for future developments and internal processes or systems whether furnished before or
after the date hereof, and whether furnished in oral, written, visual, machine readable or any other form, and regardless of the manner in which it is furnished (including by fax and any other form of electronic delivery); and (b) any document
or material prepared by the Recipient or its Representatives based on any confidential information and all copies, extracts, reproductions, summaries or analyses of any such information (whether created by the Recipient or any other Person),
including all digital and electronic copies. 
  

 3 

 “Confidentiality Agreement” means the separate agreement between GD and WWI in relation
to the non-competition and non-disclosure obligations and certain rights and obligations of each of GD and WWI, executed on the date hereof in the form attached as Appendix 5. 
 “Consumer Price Index” means the Consumer Price Index as published by the National Bureau of Statistics of China, or any successor
organization. 
 “Control” with respect to any Person, means (a) holding, whether individually or in concert with one or
more other Persons, directly or indirectly, any fraction of the capital of such Person giving the holder the majority of the voting rights of such Person; (b) holding alone the majority of the voting rights of such Person (including pursuant to
the provisions of a shareholders’, investors’ or other equity holders’ agreement, undertaking or arrangement); (c) being able, whether individually or in concert with one or more other Persons, to effectively determine decisions
taken at any such Person’s shareholders’ or other equity holders’ meetings (or pursuant to any written consent or other action in lieu thereof); or (d) being a shareholder or other equity holder of such Person and having, whether
individually or in concert with one or more other Persons, the power to appoint a majority of the members of the board of directors, management, supervisory or administrative body of such Person. The terms “Controls”,
“Controlled” and “Controlling” shall have corresponding meanings. 
 “DAP Change of
Control” means (a) a Transfer by a Person of all or a portion of the interest or rights that it directly or indirectly holds in, or with respect to, DAP to another Person such that subsequent to such Transfer, GD shall no longer
Control DAP or (b) a Transfer by the shareholders of GD or an issuance of new Equity Securities of GD such that subsequent to such Transfer or a new issuance, any Person or its Affiliates, individually or collectively, own, directly or
indirectly, more than 50% of the Equity Securities of GD on a fully diluted basis. 
 “Dispute” means any dispute,
controversy or claim arising out of, or relating to, this Agreement or the performance, interpretation, breach, termination or validity hereof other than a dispute with respect to a Deadlocked Matter. 
 “Distributable Profits” means any profits available for distribution in respect of a given Financial Year (a) after making up all
accumulated losses of previous years of, and taking into account any statutory reserves required to be made by, the Company, and (b) where the aggregate net income of the WFOEs has been greater than zero for such Financial Year. 
 “Electronic Medium” has the meaning specified in the License Agreement. 
 “Equity Securities” means, with respect to any Person, such Person’s capital stock, membership interests, partnership interests,
registered capital, joint venture or other ownership interests (including, in the case of the Company, Shares) or any options, warrants or other securities that are directly or indirectly convertible into, or exercisable or exchangeable for, such
capital stock, membership interests, partnership interests, registered capital, joint venture or other ownership interests (whether or not such derivative securities are issued by such Person). 
  

 4 

 “Encumbrance” means (a) any mortgage, charge (whether fixed or floating), pledge,
lien, hypothecation, assignment, deed of trust, title retention, security interest or other encumbrance of any kind securing, or conferring any priority of payment in respect of, any obligation of any Person, including any right granted by a
transaction that, in legal terms, is not the grant of security but that has an economic or financial effect similar to the creation of a security that is legally enforceable under applicable Law, any proxy, power of attorney, voting trust agreement,
interest, option, right of first offer, negotiation or refusal or transfer restriction in favor of any Person and (b) any adverse claim as to title, possession or use. 
 “Examination and Approval Authority” means the Ministry of Commerce of the PRC or its relevant local counterpart that is legally
authorized to approve the establishment of the WFOEs pursuant to PRC Laws. 
 “Financial Quarter” means any of the quarterly
accounting periods of the Company, ending March 31, June 30, September 30 and December 31 of each year. 
 “Financial Year” means the financial year of the Company being January 1 to December 31. 
 “Five-Year Business Plan” means a five-year business plan for the operation of the Company and the WFOEs, which includes the capital and operating budgets for the Company and the WFOEs for the relevant period as well as
KPIs and MPTs for the Group. The initial Five-Year Business Plan, to be mutually agreed by the Parties, shall commence six months after the Soft Launch Date. 
 “Group” means the Company and its Subsidiaries, and a “member of the Group” means any one of them. 
 “Group EBITDA” means, for any period with respect to the Group on a consolidated basis and determined in accordance with US GAAP, the sum of: (a) the net income (or loss) of the Group for
such period (after eliminating any extraordinary gains and losses determined in accordance with US GAAP), including but not limited to the sale of businesses, and the impairment of goodwill, plus (b) all interest expense (less interest income)
of the Group for such period, plus (c) all charges against income of the Group for such period for all income taxes, plus (d) all depreciation expense of the Group for such period, plus (e) all amortization expense of the Group for
such period. 
 “Group Net Asset Value” means the difference between (a) the total value of the assets of the Group (on
a consolidated basis) as reflected on the Books as of the date of termination of this Agreement determined in accordance with US GAAP and (b) the total value of the liabilities of Group (on a consolidated basis) as reflected on the Books
as of the date of termination of this Agreement determined in accordance with US GAAP. 
  

 5 

 “Hong Kong” means Hong Kong Special Administrative Region, PRC. 
 “HK GAAP” means generally accepted accounting principles prescribed in Hong Kong in effect from time to time. 
 “IFRS” means the International Financial Reporting Standards prescribed by the International Accounting Standards Board and its
successors. 
 “Indebtedness” means, at any time with respect to the Group on a consolidated basis and determined in
accordance with US GAAP and without duplication: (a) all obligations for borrowed money or advances, (b) all obligations evidenced by bonds, debentures, notes or similar instruments, (c) all obligations upon which interest
charges are customarily paid or accrued, (d) all obligations under conditional sale or other title retention agreements relating to property purchased by the Group, (e) all obligations issued or assumed as the deferred purchase price of
property or services (but excluding trade accounts payable or accrued liabilities arising in the ordinary course of business which are not overdue or which are being contested in good faith), (f) all capital lease obligations, purchase money
obligations and synthetic lease obligations to the extent that such synthetic lease obligations are structured as capital leases, (g) all obligations for reimbursement of any obligor in respect of letters of credit, letters of guaranty, and
similar credit transactions, (h) all obligations in respect of Indebtedness of any other Person (including any partnership in which any member of the Group is a general partner) to the extent that any member of the Group is liable therefor as a
result of its ownership interest in or other relationship with such Person and that such Indebtedness has been approved by the Board unanimously, except to the extent that the terms of such Indebtedness provide that such member of the Group is not
liable therefor and (i) every obligation, contingent or otherwise, guarantying, or having the economic effect of guarantying or otherwise acting as surety for, any obligation of a type described in any of clauses (a) through (j) of
another Person, in any manner, whether directly or indirectly. 
 “Laws” means all applicable laws, regulations, rules and
orders of any governmental authority, securities exchange or other self-regulatory body, including any ordinance, statute or other legislative measure and any regulation, rule, treaty, order, decree or judgment. 
 “License Agreement” means the Intellectual Property License Agreement between WWI and the Company, in the agreed form attached hereto as
Appendix 4 and executed on the Company Establishment Date pursuant to Section 4.4, as may be amended from time to time. 
 “Licensed Business” has the meaning specified in the License Agreement. 
 “Lock-Up Period” means
the period ending on the fifth anniversary of the WFOE Establishment Date of the Shanghai WFOE. 
 “Long Stop Date” means the
date that is twelve months from the date of this Agreement. 
  

 6 

 “Macau” means Macau Special Administrative Region of the PRC. 
 “Net Indebtedness” means, at any time with respect to the Group on a consolidated basis and determined in accordance with US GAAP,
the Indebtedness after deducting the aggregate amount of cash and cash equivalent investments (being all bonds, notes, certificates of deposit and commercial paper with a maturity of not more than twelve months) held by any member of the Group.

 “Other Agreements” means (a) the Confidentiality Agreement, (b) the Services Agreement and (c) any other
agreements between the Parties or their respective Affiliates executed on the date hereof. 
 “Permitted Affiliate” of a
Party means a Person with respect to which GD (if such Party is DAP) or WWI (if such Party is WTW), as the case may be, directly or indirectly legally or beneficially owns at least 95% of the Equity Securities. 
 “Person” means any individual, firm, corporation, joint venture, enterprise, partnership, trust, unincorporated association, limited
liability company, government (or agency or political subdivision thereof), or other entity of any kind, whether or not having separate legal personality. 
 “PRC” or “China” means the People’s Republic of China. 
 “PRC
GAAP” means generally accepted accounting principles prescribed in the PRC in effect from time to time. 
 “PRC
Laws” means the Laws of the PRC. 
 “SAIC” means the State Administration of Industry and Commerce of the PRC or its
local branches as appropriate to the context. 
 “Services Agreement” means the Services Agreement between DAP and the
Company, in the agreed form attached hereto as Appendix 2 and executed on the Company Establishment Date pursuant to Section 4.4, as may be amended from time to time. 
 “Shanghai” means the municipality of Shanghai as defined by the PRC government. 
 “Shanghai WFOE Approvals” means such rights, licenses, permits, approvals, waivers, consents and authorizations that are necessary for
the Shanghai WFOE to engage in the business activities contemplated in this Agreement as set forth in Appendix 6. 
 “Shareholders” means (i) DAP and WTW and (ii) any other Person who becomes a shareholder of the Company in accordance with the terms of this Agreement and executes a Deed of Adherence substantially in the form
attached hereto as Appendix 3, in each case for so long as such Person remains a shareholder of the Company, and in the case of any Shareholder that is a 

  

 7 

 
natural person shall be deemed to include the estate of such Shareholder and the executor, conservator, committee or other similar legal representative of
such Shareholder or such Shareholder’s estate following the death or incapacitation of such Shareholder. 
 “Shares”
means the ordinary shares, par value HK$1.00, of the Company. 
 “Soft Launch Date” means the date that is twelve months from
the date of this Agreement. 
 “Subsidiary” means any other Person in which the Company directly or indirectly holds a
majority of the ownership interests, or a majority of the voting power, represented by Equity Securities of such Person, including the WFOEs. 
 “Territory” means the PRC. For the avoidance of doubt, Taiwan, Hong Kong and Macau shall not be considered part of the Territory. 
 “Transfer” means, whether voluntarily or involuntarily, to give, sell, issue, assign, pledge, encumber, hypothecate, grant a security interest in or otherwise dispose or convey, whether in one
transaction or a series of related transactions. The terms “Transferee,” “Transferor,” “Transferred” and other forms of the word “Transfer” shall have the correlative meanings.

 “U.S.” means the United States of America. 
 “US GAAP” means generally accepted accounting principles as prescribed by the Financial Accounting Standards Board of the U.S. in effect from time to time. 
 “WFOE Establishment Date” means, with respect to each WFOE, the date the business license for such WFOE is issued by SAIC. 
 “WTW Buyout Price” means the amount equal to the product of (a) the Buyout Price and (b) a fraction, the numerator of which
shall be the number of Shares held by DAP and the denominator of which shall be the total number of Shares outstanding. 
 “WTW Change
of Control” means (a) a Transfer by a Person of all or a portion of the interest or rights that it directly or indirectly holds in, or with respect to, WWI to another Person such that subsequent to such Transfer, a Person other than
Artal or its Affiliates Controls WWI or (b) receipt by WTW of a written notice from Artal that Artal and its Affiliates intend to relinquish Control of WWI. 
  

	1.2	Other Terms. The following terms shall have the meanings defined in the Section indicated: 

  

			
	 Term
	  	Section
	 Acceptance Notice
	  	5.4(a)
	 Agreement
	  	Preamble
	 Annual Plan
	  	12.3(a)

  

 8 

			
	 Term
	  	Section
	 Approved Information
	  	9.2(a)(iii)
	 Auditor
	  	10.2
	 Buyout Notice
	  	14.2
	 CFO
	  	9.1(a)
	 Chairman
	  	8.1(c)
	 Company
	  	Recitals
	 DAP
	  	Preamble
	 DAP Change of Control Notice
	  	5.6
	 DAP Directors
	  	8.1(a)
	 DAP Interest Value
	  	5.6(a)
	 DAP Notice
	  	5.6(a)
	 DAP Shares
	  	4.1(a)
	 Deadline
	  	12.3(a)
	 Deadlock Date
	  	8.10(a)
	 Deadlock Exercise Notice
	  	8.10(e)
	 Deadlock Notice
	  	8.10(b)
	 Deadlock Option
	  	8.10(a)
	 Deadlock WTW Interest Value
	  	8.10(e)
	 Deadlock WTW Notice
	  	8.10(e)
	 Deadlocked Matter
	  	8.10(a)
	 Disclosing Party
	  	1.1
	 Employer
	  	6.4
	 Exercise Notice
	  	5.6(a)
	 Financial and Accounting System
	  	9.3(b)
	 GD
	  	Recitals
	 HKIAC AC
	  	17.2(b)
	 Independent Auditor
	  	5.4(a)
	 Initial Conditions
	  	4.3(b)
	 Initial Contribution
	  	4.3(a)
	 Invoking Party
	  	8.10(d)
	 KPIs
	  	12.1
	 Milestones
	  	15.1
	 Milestone Buyout Notice
	  	15.2(a)
	 Milestone Failure Purchase Right
	  	15.1
	 MPTs
	  	12.1
	 Non-Invoking Party
	  	8.10(e)
	 Non-Terminating Party
	  	14.1
	 Offer Period
	  	5.4(a)
	 Offer Price
	  	5.4(a)
	 Offered Interest
	  	5.4(a)
	 Party
	  	Preamble
	 Permitted Affiliate Transferee
	  	5.3(a)
	 Prohibited Payment
	  	9.4(b)
	 Put-Call Option
	  	5.6(a)
	 Recipient
	  	1.1
	 Representatives
	  	7.2(a)
	 Securities Laws Obligations
	  	10.4(a)
	 Senior Managers
	  	9.1(a)
	 Shanghai WFOE
	  	Recitals

  

 9 

			
	 Term
	  	Section
	 SOXA
	  	10.4(a)
	 Submission Notice
	  	17.2(a)
	 Tag-Along Right
	  	5.5(b)
	 Terminating Party
	  	13.3(c)
	 Termination Purchase Right
	  	14.1
	 Transfer Notice
	  	5.4(a)
	 Transferring Party
	  	5.3(a)
	 Trigger Notice
	  	5.6(a)
	 WFOE
	  	Recitals
	 WFOE Term
	  	13.2(a)
	 WTW
	  	Preamble
	 WTW Change of Control Notice
	  	5.6
	 WTW Directors
	  	8.1(a)
	 WTW Shares
	  	4.1(a)
	 WWI
	  	Recitals

  

	1.3	Interpretation. 

  

	 	(a)	All headings herein are inserted only for convenience and ease of reference and are not to be considered in the construction or interpretation of any provision of this Agreement.

  

	 	(b)	Unless a clear contrary intention appears: 

  

	 	(i)	the singular number includes the plural number and vice versa; 

  

	 	(ii)	reference to any Person includes such Person’s successors and assigns but, if applicable, only if such successors and assigns are not prohibited by this Agreement, and
reference to a Person in a particular capacity excludes such Person in any other capacity or individually; 

  

	 	(iii)	reference to any gender includes each other gender; 

  

	 	(iv)	reference to any agreement, document or instrument means such agreement, document or instrument as amended or modified and in effect from time to time in accordance with the terms
thereof; 

  

	 	(v)	reference to any Law means such Law as amended, modified, codified, replaced or reenacted, in whole or in part, and in effect from time to time, including all other Laws promulgated
thereunder, and reference to any section or other provision of any Law means that provision of such Law from time to time in effect and constituting the substantive amendment, modification, codification, replacement or reenactment of such section or
other provision; 

  

 10 

	 	(vi)	references to any government ministry, agency, department or authority shall be construed as references to the duly appointed successor ministry, agency, department or authority of
such ministry, agency, department or authority where the context permits; 

  

	 	(vii)	“hereunder,” “hereof,” “hereto,” and words of similar import shall be deemed references to this Agreement as a whole and not to
any particular article, section or other provision hereof; 

  

	 	(viii)	headings are included for convenience only and shall not affect the construction of any provision of this Agreement; 

  

	 	(ix)	numbered or lettered articles, sections and subsections herein contained refer to articles, sections and subsections of this Agreement; 

  

	 	(x)	“including” (and with correlative meaning “include”) means including without limiting the generality of any description preceding such term;

  

	 	(xi)	“or” is used in the inclusive sense of “and/or”; 

  

	 	(xii)	references to documents, instruments or agreements shall be deemed to refer as well to all addenda, exhibits, schedules or amendments thereto; 

  

	 	(xiii)	any term in any Schedule or Exhibit hereto shall have the meaning ascribed to such term in this Agreement, unless otherwise defined therein; 

  

	 	(xiv)	reference to dollars or US$ shall be deemed to refer to U.S. Dollars; 

  

	 	(xv)	reference to a year or to a quarter means the fiscal year or fiscal quarter of the Company, respectively, and reference to a month means a calendar month; 

 

	 	(xvi)	if a period of time is specified and dates from a given day or the day of a given act or event, such period shall be calculated exclusive of that day; if the day on or by which
something must be done is not a Business Day, that thing must be done on or by the Business Day immediately following such day; 

  

	 	(xvii)	references to writing include any mode of reproducing words in a legible and non-transitory form; and 

  

	 	(xviii)	references to a “fully diluted basis” mean that the calculation is to be made assuming that all options, warrants and other equity securities convertible into or
exercisable or exchangeable for Shares (whether or not by their terms then currently convertible, exercisable or exchangeable). 

  

 11 

	 	(c)	It is the intention of the Parties that every covenant, term, and provision of this Agreement shall be construed simply according to its fair meaning and not strictly for or against
any Party (notwithstanding any rule of law requiring an agreement to be strictly construed against the drafting party), it being understood that the Parties to this Agreement are sophisticated and have had adequate opportunity and means to retain
counsel to represent their interests and to otherwise negotiate the provisions of this Agreement. 

 SECTION 2

 ESTABLISHMENT OF THE COMPANY AND WFOES 
  

	2.1	Establishment of the Company. The Parties agree to form, and by this Agreement do form, the Company for the purposes of conducting the Licensed Business, directly and/or
through its Subsidiaries, including the WFOEs, in multiple locations in the Territory. 

  

	2.2	Establishment of WFOEs. The Parties agree to establish WFOEs in various locations within the Territory as determined by the Board. In this connection, as soon as reasonably
practicable following the Company Establishment Date, the Company shall establish the Shanghai WFOE. Subject to approval from the relevant PRC governmental authorities, each WFOE shall have the power to conduct and operate the Licensed Business in
multiple locations throughout the Territory and shall have the power to conduct other related activities as the Parties may from time to time agree. 

  

	2.3	Name. The name of the Company shall be “Weight Watchers Danone China Limited”. If any Party together with its Affiliates do not own any Shares of the Company, such
Party may, in writing, require the Company and/or its Subsidiaries to remove any references to such Party from the name(s) of the Company and/or its Subsidiaries. Upon receipt of such Party’s written request, the other Party shall cause the
Company and/or its Subsidiaries to promptly remove the requesting Party’s name from the relevant name(s). 

  

	2.4	Limited Liability. The liability of each Party with respect to the Company shall be limited to its contribution to the share capital in accordance with Sections 4.2 and
4.3. Neither Party shall have any liability to any third party in respect of the debts or obligations of the Company. 

  

	2.5	Shareholders’ Obligations. Each Party shall comply with the provisions of this Agreement in relation to its investment in the Company and in transacting business with
the Company and shall exercise its rights and powers in accordance herewith and so as to give effect to this Agreement. 

 SECTION 3 
 SCOPE OF BUSINESS OPERATIONS 
  

	3.1	Scope of Business. The Parties shall ensure that the Company will conduct only the Licensed Business and conduct such business solely and strictly in accordance with this
Agreement and the License Agreement. 

  

 12 

	3.2	WFOE Business. The Parties shall exercise their rights and powers in respect of the Company and each WFOE so as to ensure that all the activities specified in this
Section 3 conducted by such WFOE shall be conducted within the scope permitted by the PRC Laws and the License Agreement, and that each WFOE shall, and the Parties shall provide reasonable assistance to such WFOE such that such WFOE can,
apply for all necessary licenses and permits from the relevant PRC governmental authorities in order to engage in those activities, whenever such licenses and permits are required. 

 SECTION 4 
 SHARE CAPITAL

 AND INCREASE OF SHARE CAPITAL 
  

	4.1	Authorized Capital of Company and WFOEs. 

  

	 	(a)	The authorized share capital of the Company shall be HK$10,000 divided into 10,000 Shares, par value HK$1.00 each, of which 490 Shares will be issued to DAP (representing 49% of the
ownership interest in the Company) (the “DAP Shares”) and 510 Shares will be issued to WTW (representing 51% of the ownership interest in the Company) (the “WTW Shares”). 

  

	 	(b)	Prior to the WFOE Establishment Date of each WFOE, the Company shall determine the total investment in, and the registered capital of, such WFOE. 

  

	4.2	Subscription of Shares. On the Company Establishment Date, each of DAP and WTW will simultaneously subscribe and pay for, and the Company will issue and allot to DAP and WTW,
fully paid DAP Shares and WTW Shares, respectively, in the amount of HK$490 and HK$510, respectively. 

  

	4.3	Contribution of Capital. 

  

	 	(a)	Subject to the fulfillment of the conditions specified in Section 4.3(b), each of DAP and WTW shall contribute additional capital to the Company in the form of cash or
extend loans to the Company in accordance with the loan agreements to be entered into by each Party and the Company, where each loan to be extended by a Party shall bear the same proportion to such Party’s contribution to share capital and each
loan agreement between a Party and the Company shall have the same terms and conditions mutually agreed to by the Parties, in the amounts specified in the initial Five-Year Business Plan (the “Initial Contribution”). Notwithstanding
the foregoing, the first fifteen percent (15%) of the Initial Contributions shall be paid by each of DAP and WTW within ten (10) days of its receipt of a written request from the Company. 

  

	 	(b)	 Each of DAP and WTW shall pay the remaining eighty-five percent (85%) of the Initial Contributions only after all of the conditions set forth below (the
“Initial Conditions”) have been satisfied or waived in writing by DAP and WTW. Payment of such remaining amounts shall 

  

 13 

	 	 
be made by each of DAP and WTW within ten (10) days of its receipt of a written request from the Company for all or a portion of such remaining amounts,
at one time or at different times, consistent with the Five-Year Business Plan. If any of the conditions set forth below have not been satisfied or waived in writing by DAP and WTW by the Long Stop Date, either Party shall have the right to
terminate this Agreement pursuant to Section 13.3(b)(ii). The Initial Conditions are as follows: 

  

	 	(i)	the articles of association of the Shanghai WFOE have been approved by the Examination and Approval Authority without material substantive amendments thereto;

  

	 	(ii)	the Business License has been issued to the Shanghai WFOE without altering in any material respect the Shanghai WFOE’s initial business scope as set forth in the articles of
association of the Shanghai WFOE; and 

  

	 	(iii)	the Shanghai WFOE has received all of the Shanghai WFOE Approvals. 

  

	 	(c)	All contributions to the share capital of the Company or Shareholders’ loans shall be made by the Parties in accordance with their respective shareholding percentages in the
Company at such time and pursuant to the same terms and conditions. Except for the Initial Contributions, any required contributions to the Company shall be subject to the unanimous approval of the Board as provided in Section 8.9. For
the avoidance of doubt, the Parties agree that in the event the Board approves unanimously the additional contribution to the capital of the Company by the Parties, such additional contributions shall be made either in the form of capital
contributions or Shareholders’ loans in the same proportion, and on the same terms and conditions. If the Parties are unable to agree on the form of such contributions or the terms of the Shareholders’ loans to be granted by the Parties to
the Company, then the additional contributions shall be made in the form of capital contribution. 

  

	4.4	Company Establishment Date. On the Company Establishment Date, the Parties shall: 

  

	 	(a)	subscribe their respective Shares and contribute their respective capital in accordance with Section 4.2; 

  

	 	(b)	appoint the initial directors of the Company in accordance with the Charter Documents and this Agreement; 

  

	 	(c)	cause the Company to hold the first Board meeting to authorize the execution of the License Agreement and the Services Agreement, and to adopt the Charter Documents, in the form
attached hereto as Appendix 1, and approve the initial Five-Year Business Plan; 

  

 14 

	 	(d)	execute the License Agreement in the form attached hereto as Appendix 4; and 

  

	 	(e)	execute the Services Agreement in the form attached hereto as Appendix 2. 

  

	4.5	Pre-emptive Right. If there is an issuance of new Shares (or any other type of security that is convertible into Shares) pursuant to the terms and conditions of this
Agreement and applicable Laws, each of the Parties shall have the right (but not the obligation) to subscribe for such newly issued Shares (or any other type of security that is convertible into Shares) such that subsequent to the subscription, each
Party will maintain its shareholding percentage at the shareholding percentage (on an as converted and fully diluted basis) of the Company that such Party held immediately prior to the relevant issuance of new Shares (or any other type of security
that is convertible into Shares). To the extent one Party does not elect to subscribe for such issuance of new Shares (or any other type of security that is convertible into Shares), the other Party shall have the right (but not the obligation) to
subscribe for such unsubscribed for Shares (or any other type of security that is convertible into such unsubscribed for Shares). 

 SECTION 5 
 TRANSFER OF INTEREST 
  

	5.1	Restriction on Transfer. No Party shall Transfer any Shares or any right, title or interest therein or thereto to any third party Transferee or otherwise create or permit or
suffer to be created or exist (whether by operation of law or otherwise) any Encumbrance over any Shares held by it or any right, title or interest therein or thereto for the benefit of any third party without the prior written consent of the other
Party, except as expressly permitted by this Section 5. Any purported Transfer or Encumbrance in violation of this Section 5 shall be null and void, and the Company and the Parties shall not register or recognize any such
Transfer or Encumbrance. 

  

	5.2	Transfer Conditions. Notwithstanding any other provisions of this Agreement but subject to Section 5.3 below, no Transfer may be made unless (a) the
Transferee has agreed in writing to be bound by the terms and conditions of this Agreement and the Charter Documents, which may be amended and restated to the extent that the Parties and the Transferee agree to such amendments, (b) the Transfer
complies in all respects with the other applicable provisions of this Agreement and the Charter Documents and (c) the Transferee has entered into a Deed of Adherence in the form attached hereto as Appendix 3. Notwithstanding any other
provisions of this Agreement, no Transfer may be made to a Competitor of the Non-Transferring Party. 

  

	5.3	Transfers to Affiliates. 

  

	 	(a)	 Notwithstanding Section 5.4(a), any Party may Transfer all, but not less than all, of its Shares (the “Transferring Party”) to one or
more of its Permitted Affiliates (the “Permitted Affiliate Transferee”). In such event, the Transferring Party shall provide written notice to the Board 

  

 15 

	 	 
and the other Party prior to such transfer and provide the other Party documents supporting the status of the Permitted Affiliate Transferee as a Permitted
Affiliate of the Transferring Party and evidencing that the Permitted Affiliate Transferee’s ability to perform this Agreement is not less than that of the Transferring Party. 

  

	 	(b)	The Transferring Party and the Permitted Affiliate Transferee shall enter into a share transfer contract with respect to the Transfer of the relevant Shares. The Parties shall
thereafter amend this Agreement and the Charter Documents to reflect the respective Shares held by the non-Transferring Party and the Permitted Affiliate Transferee subsequent to the completion of such share transfer contract. The Parties shall use
their reasonable commercial efforts to assist the Company to obtain all governmental approvals that may be required in relation to such transfer of shares. The Parties shall, and shall cause the Company to, promptly execute all such further
documents and perform all such further acts as the Transferring Party may reasonably require to constitute the Permitted Affiliate Transferee as the legal and beneficial owner of the interest Transferred pursuant to the Transfer free from any and
all Encumbrances (other than the Encumbrance created by this Agreement). 

  

	 	(c)	If a Transferee pursuant to this Section 5.3 ceases to be a Permitted Affiliate of the Transferring Party, such Transferee shall Transfer such Shares back to such
Transferring Party. 

  

	5.4	Right of First Refusal. 

  

	 	(a)	 At any time following the Lock-Up Period, and except as provided in Section 5.3, a Party may Transfer all, but not less than all, of its Shares provided
that the provisions of this Section 5.4 and Section 5.5 have been complied with. The Transferring Party shall send written notice (the “Transfer Notice”) to the other Party, which notice shall state
(i) the name and address of the proposed Transferee, (ii) the number of all the Shares proposed to be transferred (the “Offered Interest”), (iii) the amount and form of the proposed consideration for the Transfer and
(iv) any other terms and conditions of the proposed Transfer. In the event the proposed consideration for the Transfer includes consideration other than cash, the Transfer Notice shall include a calculation of the fair market value of such
consideration and an explanation of the basis for such calculation, further provided that the other Party shall be entitled at any time after receipt of the Transfer Notice to serve notice on the Transferring Party requiring a valuation of such
consideration by an auditor who is independent from each Party, is not the Auditor (as defined in Section 10.2 below), is one of the major international accounting firms and is capable of performing accounting work meeting both PRC
domestic accounting standards and international standards (the “Independent Auditor”), at the cost of the Transferring Party. If the aggregate fair market value as so determined by the Independent Auditor falls short of the amount
stated in the Transfer Notice, the shortfall must be covered in cash and the Transfer 

  

 16 

	 	 
Notice shall be amended accordingly. The total value of the consideration for the proposed Transfer is referred to as the “Offer Price.” For
a period of 30 days after delivery of the Transfer Notice or after completion of the valuation of consideration by the Independent Auditor (which date shall be no more than 30 days after the date on which the other Party has served notice on the
Transferring Party requiring a valuation) in the event the proposed consideration for the Transfer includes consideration other than cash (the “Offer Period”), the other Party shall have the right, exercisable by delivery of an
Acceptance Notice (as defined below), to purchase all, but not less than all, of the Offered Interests for cash at a purchase price equal to the Offer Price and upon the other terms and conditions set forth in the Transfer Notice. The right to
purchase the Offered Interest shall be exercisable by delivering written notice of exercise (an “Acceptance Notice”) within the Offer Period to the Transferring Party. An Acceptance Notice shall be irrevocable and shall constitute a
binding agreement by the other Party to purchase the Offered Interest. The failure of the other Party to give an Acceptance Notice within the Offer Period shall be deemed to be a waiver of such purchase right. Unless the other Party elects to
purchase the entire Offered Interest as provided above, the Transferring Party may Transfer the Offered Interest to the Transferee identified in the Transfer Notice on the terms and conditions set forth in the Transfer Notice; provided that
(1) the price for the sale to the Transferee is a price not less than the Offer Price and the sale is otherwise on terms and conditions no less favorable to the Transferring Party than those set forth in the Transfer Notice and (2) the
Transfer is made within 60 days after the end of the Offer Period or such other time period as the Parties may mutually agree. If such a Transfer does not occur within such time period referred to in Clause (2) for any reason, the restrictions
provided for herein shall again become effective, and no Transfer may be made by the Transferring Party thereafter without again making an offer to the other Party in accordance with this Section 5.4. 

  

	 	(b)	 The closing of any purchase of Offered Interest shall be held at the principal office of the Company at 11:00 a.m. local time on the 60th day after the end of the
Offer Period or at such other time and place as the parties to the transaction may agree. The said 60 day period shall be extended for an additional period of up to 30 days if necessary to obtain any regulatory approvals required for such purchase
and payment. At such closing, the Transferring Party shall deliver certificates representing the Offered Interest, accompanied by duly executed instruments of transfer and the Transferring Party’s portion of the requisite transfer taxes, if
any. Such Offered Interest shall be free and clear of any Encumbrance (other than Encumbrances arising hereunder or attributable to actions by the other Party) and the Transferring Party shall so represent and warrant and shall further represent and
warrant that it is the beneficial and record owner of such Offered Interest. The other Party or the Transferee (as the case may be) shall deliver at such closing (or on such later date or dates as may 

  

 17 

	 	 
be provided in the Transfer Notice with respect to payment of consideration by the proposed Transferee) payment in full of the Offer Price by wire transfer
of immediately available funds, or duly executed instruments of transfer and all other documents required in connection with such transfer, and take all actions necessary for the transfer of rights, title and ownership of the non-cash consideration
(as the case may be). At such closing, all of the parties to the transaction shall execute such additional documents as may be necessary or appropriate to effect the sale of the Offered Interest. Any stamp duty or transfer taxes or fees payable on
the transfer of any Offered Interest shall be borne and paid equally by the Transferring Party and the other Party or the Transferee (as the case may be). 

  

	5.5	DAP Tag-Along Right. 

  

	 	(a)	If WTW is the Transferring Party in a proposed Transfer other than pursuant to Section 5.3, the Transfer Notice delivered by WTW as the Transferring Party pursuant to
Section 5.4 shall include, in addition to those items specified in Section 5.4(a), (i) the number of Shares WTW then owns, (ii) the expected date of consummation of the proposed Transfer and (iii) a
representation that the proposed Transferee has been informed of the Tag-Along Rights provided for in Section 5.5(b) and has agreed to purchase all Shares required to be purchased in accordance with the terms of this
Section 5.5. 

  

	 	(b)	If DAP does not exercise its right to purchase the Offered Interest of WTW pursuant to Section 5.4, DAP shall have the right (the “Tag-Along Right”) but
not the obligation to require the Transferee in such Transfer to purchase from DAP, for the same consideration per Share and upon the same terms and conditions as to be paid and given to WTW, all of the Shares held by DAP. 

 

	 	(c)	Tag-Along Notice. DAP may exercise its Tag-Along Right by delivering a written notice of such election to WTW before the expiration of the Offer Period, specifying the number
of Shares with respect to which it has elected to exercise its Tag-Along Right. Such notice shall be irrevocable and shall constitute a binding agreement by DAP to Transfer such Shares on the terms and conditions set forth in the Transfer Notice. In
order to be entitled to exercise its Tag-Along Right, DAP must make substantially the same representations, warranties and indemnities as WTW makes in connection with its Transfer of Shares and shall bear, on a pro rata basis, all third party costs
and expenses incurred in connection with the sale of the Shares, up to a maximum amount of 4% of the consideration for the Offered Interest, upon receipt of properly issued invoices provided by the relevant third party service providers evidencing
any such third party costs and expenses to the extent that any such third party service providers have provided any properly issued invoices, provided that, WTW shall use reasonable efforts to procure properly issued invoices from such third
party service providers. 

  

 18 

	 	(d)	Consummation. Where DAP has properly elected to exercise its Tag-Along Right and the proposed Transferee fails to purchase Shares from DAP, WTW shall not make the proposed
Transfer, and if purported to be made, such Transfer shall be void. 

  

	5.6	Change of Control. If at any time DAP becomes aware that a DAP Change of Control has or is about to occur, DAP shall immediately deliver a notice to WTW (the “DAP
Change of Control Notice”). If at any time WTW becomes aware that a WTW Change of Control has or is about to occur, WTW shall immediately deliver a notice to DAP (the “WTW Change of Control Notice”) . If a WTW Change of
Control or a DAP Change of Control occurs, WTW may elect to invoke the following put-call option: 

  

	 	(a)	The “Put-Call Option” shall consist of the following: WTW may invoke the Put-Call Option by delivering a written notice to DAP (the “Trigger
Notice”): (A) within 30 days after WTW receives the DAP Change of Control Notice or (B) within 6 months after WTW delivers the WTW Change of Control Notice. Within 30 days of DAP receiving the Trigger Notice, DAP shall deliver to
WTW a notice (the “DAP Notice”) setting forth its determination of the value of its interest in the Company (the “DAP Interest Value”). Upon receipt thereof, WTW shall have the right, exercisable by written notice
(the “Exercise Notice”) to DAP delivered within six months following receipt of the DAP Notice, to either purchase the entire interest of DAP at a price equal to the DAP Interest Value or to sell its entire interest in the Company
to DAP at a price equal to the product of (i) the DAP Interest Value, and (ii) a fraction, the numerator of which shall be the number of Shares held by WTW and the denominator of which shall be the number of Shares held by DAP. The
Exercise Notice shall be irrevocable and, together with the DAP Notice, shall constitute a binding agreement by the Parties to purchase and sell the applicable interest of the selling Party in the Company. The closing of the sale of the interest in
the Company of DAP or WTW, as applicable, shall occur on a date to be determined by WTW, but in any event not later than 90 days following delivery to DAP of the Exercise Notice. At such closing, the selling Party shall deliver such duly executed
instruments of transfer and other documents required in connection with such transfer and the purchasing Party shall deliver payment in full by wire transfer of immediately available funds. The interests being transferred shall be free and clear of
any Encumbrance (other than Encumbrances arising under this Agreement) and the selling Party shall so represent and warrant, and shall further represent and warrant that it is the beneficial and record owner of such interest being transferred.

  

	 	(b)	For the avoidance of doubt, WTW confirms that if it exercises its Put-Call Option to sell its entire interest in the Company to DAP in accordance with this Section 5.6
the License Agreement shall continue to be in force (save for termination due to any breach of the License Agreement by the Company thereunder). 

  

 19 

	5.7	Avoidance of Restrictions. The Parties agree that the Transfer restrictions in this Agreement and in the Charter Documents shall not be capable of being avoided by the
holding of Shares indirectly through a Person that can itself be sold in order to dispose of an interest in Shares free of such restrictions. Any Transfer or other disposal of any Shares (or other interests) resulting in any change in the Control of
a Shareholder or of any Person having Control over that Shareholder shall be treated as being a Transfer of the Shares held by that Shareholder, and the provisions of this Agreement and the Charter Documents that apply in respect of the Transfer of
Shares shall thereupon apply in respect of the Shares so held; provided however, any Transfer or other disposal of shares of WWI or GD by any of their respective shareholders shall not be subject to this provision or any restriction or limitation,
except however, if any such Transfer or other disposal of shares of WWI or GD results in a WTW Change of Control or a DAP Change of Control, as the case may be, the provisions set forth in Section 5.6 shall apply.

  

	5.8	Transfer of Convertible Securities. Any Transfer of Equity Securities exercisable or convertible into or exchangeable for Shares will be deemed for the purposes of this
Section 5 to be a Transfer of Shares. 

  

	5.9	Notice of Transfer. Within five Business Days after registering any Transfer of Shares or other Equity Securities on its Books, the Company shall send a notice to each
Shareholder stating that such Transfer has taken place and setting forth the name of the Transferor, the name of the Transferee and the number and class of Equity Securities involved. 

 SECTION 6 
 CONDITIONS FOR
COOPERATION AND 
 RESPONSIBILITIES OF THE PARTIES 
  

	6.1	Responsibilities of DAP. In addition to its responsibilities set forth elsewhere in this Agreement, DAP shall perform the following duties: 

  

	 	(a)	make its contributions to the share capital of the Company in the form and manner and at the times required by this Agreement and the Charter Documents; 

  

	 	(b)	fulfill its obligations, and ensure that its Affiliates fulfill their obligations, if any, as set forth in the Services Agreement and the Other Agreements to which DAP or any of its
Affiliates is a party; 

  

	 	(c)	take all actions necessary jointly with WTW to establish the Company in Hong Kong and procure that the Company establish the Shanghai WFOE as soon as practicable and all other WFOEs
as and when determined by the Board, including preparing and filing the Charter Documents and the articles of association of such WFOEs (which shall be in English and Chinese) in accordance with the provisions of this Agreement and the Charter
Documents, and obtaining all WFOE Approvals for such WFOEs; 

  

 20 

	 	(d)	cause its representatives on the Board to implement the Five-Year Business Plan approved by the Board and to perform and take all actions in accordance with this Agreement, the
Charter Documents, the License Agreement, the Services Agreement, the Other Agreements and the intent of the Parties; 

  

	 	(e)	together with WTW, jointly assist the Company in obtaining and maintaining in force all WFOE Approvals and agreements that are necessary for the Company and the WFOEs to achieve
their respective goals and business objectives and cause the Company to conduct the business of the Company (through any WFOE and otherwise) in accordance with the terms of this Agreement, the Charter Documents, the License Agreement, and the Other
Agreements; 

  

	 	(f)	use reasonable efforts to leverage the governmental relations expertise in the Territory of DAP, its Affiliates, and the Danone Institute to facilitate the Company’s access to
relevant public and private sector individuals and organizations, including in the nutritional area (WTW acknowledging the Danone Institute are independent of DAP and its Affiliates); and 

  

	 	(g)	assist the Company in other matters as reasonably requested by the Board. 

  

	6.2	Responsibilities of WTW. In addition to its responsibilities set forth elsewhere in this Agreement, WTW shall perform the following duties: 

  

	 	(a)	make its contributions to the share capital of the Company in the form and manner and at the times required by this Agreement and the Charter Documents; 

  

	 	(b)	fulfill its obligations, and ensure that its Affiliates fulfill their obligations, set forth in the License Agreement and Other Agreements to which WTW or any of its Affiliates is a
party; 

  

	 	(c)	take all actions necessary jointly with DAP to establish the Company in Hong Kong and procure that the Company establish the Shanghai WFOE as soon as practicable and all other WFOEs
as and when determined by the Board, including preparing and filing the Charter Documents and the articles of association of such WFOEs (which shall be in English and Chinese) in accordance with the provisions of this Agreement and the Charter
Documents, and obtaining all WFOE Approvals for such WFOEs; 

  

	 	(d)	cause its representatives on the Board to implement the Five-Year Business Plan approved by the Board, and to perform and take all actions in accordance with this Agreement and the
Charter Documents, the License Agreement, the Services Agreement, the Other Agreements and the intent of the Parties; 

  

 21 

	 	(e)	together with DAP, jointly assist the Company in obtaining and maintaining in force all WFOE Approvals and agreements that are necessary for the Company and the WFOEs to achieve
their respective goals and business objectives and cause the Company to conduct the business of the Company (through any WFOE and otherwise) in accordance with the terms of this Agreement, the Charter Documents, the License Agreement, and the Other
Agreements; 

  

	 	(f)	nominate one Person to serve as the Company’s initial CEO; and 

  

	 	(g)	assist the Company in other matters as reasonably requested by the Board. 

  

	6.3	Non-Competition. 

  

	 	(a)	During the period commencing on the date hereof and ending on the later of (i) June 20, 2011 and (ii) three years after the earliest date that neither DAP nor any of
its Affiliates own any interests in the Company, DAP shall not, and shall ensure that its Affiliates shall not, (1) compete, either directly or indirectly, with the Approved Lines within or outside the Territory or (2) provide services to
the general public (either directly or indirectly) in relation to encouraging or monitoring weight management through meetings, classes, one-on-one instruction or paid Electronic Medium subscriptions within or outside the Territory, provided
that, nothing in this Section 6.3 shall restrict DAP’s and its Affiliates’ right to: (x) produce and sell any food and beverage products, including any such products in the weight loss/healthy living industry and
(y) create, own, manage or otherwise engage in activities in relation to gym clubs, sports clubs, spas and other establishments of a similar nature. 

  

	 	(b)	During the period commencing on the date hereof and ending on the later of (i) the earliest date that neither WTW nor any of its Affiliates own an interest in the Company and
(ii) the earliest date that the License Agreement is no longer in effect, WTW shall not, and shall ensure that its Affiliates shall not, compete, either directly or indirectly, with the Approved Lines within the Territory; provided that
WTW and its Affiliates may engage in any activity in the Territory in relation to any rights reserved by WTW and not granted to the Company under the License Agreement. 

  

	6.4	 Non-Solicitation. Each of the Parties shall not, and shall cause the Company and Affiliates not to (a) directly or indirectly induce or attempt to
induce or otherwise counsel, advise, ask or encourage any person who is at the time, or was at any time within the preceding six (6) months, employed by the other Party or any of its Affiliates (the “Employer”), to leave the employ of
such Employer or to accept employment with another employer or as an independent contractor or (b) offer employment to or retain the services of such person, other than with the consent of the Employer. This Section 6.4 shall not
apply to an employee who becomes employed by a Party or by the Company as a result of a response by that employee to a public advertisement 

  

 22 

	 	 
or normal recruitment procedures and not as a result of being approached or targeted by such Party or the Company. The obligations of this
Section 6.4 shall continue to survive for eighteen (18) months after the expiration or termination of this Agreement. 

 SECTION 7 
 CONFIDENTIAL INFORMATION, 
 PUBLICITY AND INTELLECTUAL PROPERTY RIGHTS 
  

	7.1	Confidential Information. The Recipient of any Confidential Information while this Agreement is in effect shall: 

  

	 	(a)	keep the Confidential Information confidential; 

  

	 	(b)	keep the Confidential Information secure so as to prevent unauthorized access by any third party, and not make any copies or reproduce the Confidential Information except for the
purpose of disclosing such Confidential Information in accordance with this Section 7. 

  

	 	(c)	not disclose the Confidential Information to any Person other than with the prior written consent of the Company or the Party that disclosed such Confidential Information, as the
case may be, or in accordance with Sections 7.4; and 

  

	 	(d)	not use the Confidential Information for any purpose other than the performance of its obligations under this Agreement. 

  

	7.2	Disclosure of Information. 

  

	 	(a)	The Recipient may disclose the Confidential Information to its directors, officers, employees, agents, consultants and advisors (collectively, the
“Representatives”), who are actually engaged in, and need to know, the Confidential Information for the purposes expressly set forth in this Agreement, who have been informed of the confidential nature of the Confidential
Information, who have been advised that such information is to be kept confidential and who have entered into enforceable written confidentiality agreements with the Recipient agreeing that the Confidential Information shall not be used for any
other purpose. The Recipient agrees that it shall (i) cause its Representatives to observe all terms of this Section 7 of and (ii) be responsible for any breach of this Section 7 by any of its Representatives.

  

	 	(b)	 The Parties agree that Confidential Information shall not include information that: (i) is already known to the Recipient without restriction on use or
disclosure prior to receipt of such information from the Disclosing Party or its Affiliates; (ii) is or becomes part of the public domain other than by breach of this Agreement, or other wrongful act, by the Recipient; (iii) is developed
by the Recipient independently of and without reference to any Confidential Information; or (iv) is received by the Recipient from a third party who 

  

 23 

	 	 
is not under any obligation to maintain the confidentiality of such information. The Recipient shall have the obligation of demonstrating that such an
exception to the definition of Confidential Information exists. 

  

	7.3	Specific Performance. The Recipient acknowledges and agrees that the Disclosing Party would be irreparably damaged by any unauthorized disclosure or use of any Confidential
Information in violation of this Section 7. Without prejudice to the rights and remedies otherwise available to the Disclosing Party, the Recipient, therefore, agrees that the Disclosing Party shall be entitled, without the requirement
of posting a bond or other security, to equitable relief, including an injunction or specific performance, in the event of any breach or threatened breach of the provisions of this Section 7 by the Recipient or its Representatives. Such
remedies shall not be deemed to be exclusive remedies but shall be in addition to all other remedies available at law or equity to the Disclosing Party. 

  

	7.4	Conditions for Disclosure. In the event that the Recipient or any of its Representatives become legally compelled (by deposition, interrogatory, request for documents,
subpoena, civil investigation, demand, order or other legal process) to disclose any of the contents of the Confidential Information, the Recipient shall, to the extent that it does not violate any applicable Law, (i) promptly notify the
Disclosing Party prior to any such disclosure to the extent practicable and (ii) cooperate with the Disclosing Party in any attempts it may make to obtain a protective order or other appropriate assurance that confidential treatment shall be
afforded the Confidential Information. 

  

	7.5	Return of Information. Upon the expiration or termination of this Agreement for whatever reason, the Recipient shall, at its own expense: 

  

	 	(a)	return to the Disclosing Party all Confidential Information (including all copies thereof) received by it or its Representatives prior to the termination of this Agreement,
provided that, to the extent that it is impractical to return any Confidential Information described in this Section 7.5(a), such Confidential Information (including all copies thereof) may be destroyed; 

 

	 	(b)	use its commercially reasonable efforts to delete any Confidential Information from any computer, word processor or other similar device, provided that, this
Section 7.5(b) shall not reduce the obligations of the Recipient in relation to Confidential Information hereunder; and 

  

	 	(c)	certify in writing to the Disclosing Party that it has destroyed, deleted or returned all Confidential Information (including all copies thereof), provided that the Recipient
may retain one copy of the Confidential Information to the extent required by law or any applicable governmental or regulatory authority, so long as such requirement is described in reasonable detail by written notice to the Disclosing Party and the
Recipient protects the confidentiality of the Confidential Information with the same degree of care as the Recipient normally uses in the protection of its own confidential and proprietary information but in no case with any less than reasonable
care. 

  

 24 

 For the avoidance of doubt, the provisions of this Section 7.5 shall not be applicable to financial
statements of the Company provided to each Party pursuant to the terms of this Agreement. 
  

	7.6	No Publicity. No Party shall, and each Party shall cause each of its Affiliates and the Company not to, make any announcement about the Company, any Subsidiary, this
Agreement or the other Party in relation to the Company, this cooperation or the business of the Company or any Subsidiary without the prior written consent of the other Party. Notwithstanding the foregoing, either of the Parties may at any time
make announcements: (a) that are required by Laws applicable to such Party or any of its Affiliates, so long as the Party so required to make the announcement, promptly upon learning of such requirement, notifies in writing the other Party of
such requirement and, to the extent practicable, discusses with the other Party in good faith the exact wording of any such announcement and takes precautionary measures to prevent disclosure of Confidential Information to the maximum extent
permitted, (b) of information that has been previously announced by either Party in accordance with this Section 7.6 or (c) of any Approved Information. 

  

	7.7	Ownership. The Confidential Information of the Disclosing Party shall remain the property of the Disclosing Party and the disclosure of any Confidential Information by the
Disclosing Party shall not confer on the Recipient any right over such Confidential Information unless otherwise specified hereunder. 

  

	7.8	No Representation. Unless otherwise specified hereunder, the Disclosing Party shall have no responsibility or liability resulting from the Recipient’s receipt or use of
any Confidential Information, and makes no representation or warranty, express or implied, in respect of any Confidential Information or the accuracy, completeness or reasonableness thereof or that such Confidential Information will remain
unchanged. 

 SECTION 8 
 CORPORATE GOVERNANCE 
  

	8.1	Board of Directors. 

  

	 	(a)	Number and Composition. The number of directors constituting the entire Board shall initially be five. Each Shareholder shall vote its Shares at any Shareholders’
meeting called for the purpose of filing positions on the Board or in any written consent of Shareholders executed for such purpose to elect, and shall take all other actions necessary to ensure the election to the Board of, (i) three nominees
of WTW (the “WTW Directors”) and (ii) two nominees of DAP (the “DAP Directors”). The term of office of the directors shall be three years, renewable upon reappointment by the appointing Party.

  

 25 

	 	(b)	Renewal and Replacement of Director. 

  

	 	(i)	Each Party shall have the right, at any time, to remove with or without cause and replace any director appointed by it, before the expiration of his or her term. If a director is
removed, becomes incapacitated, dies, resigns or otherwise ceases to be a director, the Party that appointed such director shall appoint a new director to serve for the remainder of the term of office of such former director.

  

	 	(ii)	Subject to Section 8.1(a), each Party shall have the right to appoint such directors to the Board that is directly proportionate to its percentage ownership interest of
the Company, in each case including in such calculation of percentage ownership interest any Shares held by their respective Permitted Affiliate Transferees, rounded to the nearest whole number. If there is a change in percentage ownership interest
of either Party (together with its Permitted Affiliate Transferees) affecting the number of directors such Party has the right to appoint to the Board, the Party whose percentage ownership interest is reduced shall remove, or procure the resignation
of, the appropriate number of directors appointed by such Party in accordance with its decreased percentage interest, and the Party whose percentage ownership interest is increased shall have the right to appoint an additional number of directors in
accordance with its increased percentage interest. 

  

	 	(c)	Chairman. So long as WTW owns a majority of the interests in the Company, WTW shall have the right to appoint the chairman of the Board (the “Chairman”) from
among WTW Directors, and shall have the right to appoint the chairman of the board of directors of each WFOE. 

  

	 	(d)	No Compensation of Directors. Directors of the Company shall not receive a salary from the Company. The Company, however, shall pay all reasonable expenses incurred by the
directors in attending Board meetings or carrying out any actions authorized by the Board, including travel expenses and accommodation. 

  

	 	(e)	Indemnification of Directors. The Company shall indemnify each director against all claims and liabilities incurred by reason of his being a director of the Company, provided
that the director’s acts or omissions giving rise to such claim or liability did not constitute gross negligence, intentional or willful misconduct or fraud. 

  

	 	(f)	Directors’ Access. Each director shall be entitled to examine the Books and shall have free access, at all reasonable times and with prior written notice, to any and all
properties and facilities of the Group. The Company shall provide such information relating to the business affairs and financial position of the Group as any director may reasonably require. Any director may provide such information to a
Shareholder. 

  

 26 

	8.2	Authority of the Board. The Board shall be the highest authority of the Company and shall direct the overall supervision and control of the business of the Company. The Board
shall be required to make all major decisions of the Company as well as all decisions outside the day-to-day business of the Company (including those referred to in Section 8.9); provided that the Board shall delegate certain of
its authority over day-to-day operational and managerial matters to the CEO. The resolutions of the Board shall be adopted in accordance with this Agreement, the Charter Documents and applicable Laws. 

  

	8.3	Frequency and Location of Board Meetings. 

  

	 	(a)	Regular meetings of the Board shall be convened on a monthly basis during the first year following the Company Establishment Date and, thereafter shall be convened on a quarterly
basis. Meetings shall be held in a location approved by a majority of the directors, and convened and presided over as provided in the Charter Documents. Special meetings of the Board shall be held in a location approved by a majority of the
directors, and convened by the Chairman at any time on his own motion or on the motion of any two directors. 

  

	 	(b)	The reasonable costs of attendance of directors at Board meetings shall be borne by the Company. 

  

	8.4	Quorum. The number of directors constituting at least two-thirds of the total number of directors elected to the Board; provided that at least one director is from
each of WTW and DAP, present in person or by proxy throughout the entire meeting, shall constitute a quorum for all meetings of the Board. If such a quorum is not present within one hour after the time appointed for the commencement of the meeting,
the meeting shall be adjourned to such place and time (which is at least ten days later or such earlier date as shall be agreed by all the directors) as the directors who did attend shall decide. If a quorum is not present within one hour after the
time appointed for the commencement of such adjourned meeting, any number of directors present shall constitute a quorum. 

  

	8.5	Proxy. If a director is unable to attend any Board meeting, such director may appoint a proxy to represent such director at such meeting and to vote on such director’s
behalf. Every appointment of a proxy shall be made in writing, signed by the director by whom it is made, and shall be sent or delivered to the chairman of the meeting for which it is given at, or prior to, the commencement of such meeting. Delivery
of a proxy by facsimile shall be effective for this purpose. A proxy need not be a director of the Company. A director may be appointed as proxy for another director, and the same Person may be appointed as proxy for more than one director. A proxy
shall have one vote for each director whom he represents, and shall also be entitled to cast one vote in his own behalf if he is, in addition, a director in his own right. 

  

	8.6	Written Resolutions. Any action to be taken at any Board meeting may be taken without a meeting if all directors consent to such action in writing. 

 

 27 

	8.7	Telephonic Participation. Board meetings may be held by telephone, video conferencing or any other means of contemporaneous communication, so long as all directors taking
part in a meeting so held are able to hear each other at the same time. Participation by such means shall be deemed to constitute presence in person at a Board meeting. The minutes of all Board meetings shall be kept on file by the Company.

  

	8.8	Notice. A meeting may be called by the Chairman or any two other directors giving notice in writing to the secretary of the Company specifying the date, time and agenda for
such meeting. The secretary of the Company shall upon receipt of such notice give a copy of such notice to all directors of such meeting, accompanied by a written agenda specifying the business of such meeting and copies of all papers relevant for
such meeting. Not less than 14 days’ notice shall be given to all directors; provided, however, that such notice period (i) shall not apply in the case of an adjourned meeting pursuant to Section 8.4 and (ii) may be
reduced with the written consent of all of the directors. 

  

	8.9	Voting. At any Board meeting, each director may exercise one vote. Decisions with respect to all matters that require approval of the Board (other than those set forth in
this Section 8.9) shall be adopted if they receive the affirmative vote of a simple majority of the directors present and voting in person or by proxy. Notwithstanding any other provision of this Agreement, (i) decisions with
respect to those matters that are required by the Laws of Hong Kong at the time the relevant resolution is adopted to be approved by unanimous approval of the Board shall require the unanimous approval of the Board and (ii) the following
actions set forth in this Section 8.9 may not be taken by the Company or any Subsidiary without the unanimous approval of the directors present at a duly constituted meeting of the Board or the unanimous written consent of all members of
the Board: 

  

	 	(a)	any agreement to make any capital expenditure in excess of US$2 million; 

  

	 	(b)	any single transaction or series of related transactions pursuant to which the Company or any Subsidiary would incur any financial commitments or indebtedness in excess of US$2
million; 

  

	 	(c)	any material purchase, supply or marketing contract involving aggregate payments in excess of US$2 million; 

  

	 	(d)	the entering into of any related party transaction by the Company or any Subsidiary with either Party or any Affiliate of a Party (including the entering into of any
Shareholder’s loans between any Party and the Company, but not including the entering into of the License Agreement, the Services Agreement and the Other Agreements, or any transactions entered into with a related party contemplated by and/or
for the purposes of implementing the License Agreement , the Services Agreement or any Other Agreement); 

  

 28 

	 	(e)	the appointment or change of auditors of the Company or any Subsidiary, provided that the Parties agree to change auditors as necessary to comply with applicable Laws;

  

	 	(f)	any distribution of profits of the Company or any Subsidiary by way of dividend, capitalization of reserves or otherwise, except as provided in Section 11;

  

	 	(g)	any change to the accounting policies of the Company; 

  

	 	(h)	any settlement, compromise or resolution of material litigation, arbitration, mediation or other material dispute resolution procedures (and, for this purpose, in considering
whether the matter is “material,” any effect such litigation, arbitration, mediation or other dispute resolution procedures may have on WTW or its Affiliates and licensees within and outside the Territory shall be considered);

  

	 	(i)	any change to the size of the Board or the board of directors of any Subsidiary; 

  

	 	(j)	the appointment (but not the removal) of the chief financial officer (or its equivalent) of the Company or any Subsidiary; 

  

	 	(k)	any determination of compensation (including cash and stock option compensation) of the top five executives of the Company or any Subsidiary, if the amount of compensation exceeds
the range specified in the guidelines provided by WTW and agreed by both Parties, other than annual increases to compensation based on changes in the Consumer Price Index; 

  

	 	(l)	any amendment, modification, waiver or termination of the License Agreement; 

  

	 	(m)	any material change in the scope or nature of the business or activities of the Company or any Subsidiary; 

  

	 	(n)	the entry by the Company or any Subsidiary into or termination of any partnership or joint venture agreement or the acquisition of or merger with any other business;

  

	 	(o)	the disposal of any material part of the Licensed Business or assets of the Company involving aggregate payments in excess of US$2 million; 

  

	 	(p)	the termination or dissolution of, or the entering into of bankruptcy, insolvency or receivership by, the Company or any Subsidiary; 

  

	 	(q)	any approval or amendment of any Five-Year Business Plan, including the KPIs and MPTs, or the Annual Plan as set forth in Section 12.3; 

  

	 	(r)	the calling of capital contributions for the Company or any Subsidiary (excluding any firm capital commitments for the establishment of any Subsidiary or any mandatory requirements
to make capital contributions as required under applicable Laws); 

  

 29 

	 	(s)	any issuance, purchase or redemption of any Shares of the Company or equity interest of any Subsidiary, or any securities that can be converted into Shares or equity interest of any
Subsidiary of the Company, or any change of the share capital structure of the Company or in the registered capital or share capital structure of any Subsidiary; 

  

	 	(t)	any amendment to the Charter Documents or the articles of association of any Subsidiary; 

  

	 	(u)	the public offering of securities of the Company or any Subsidiary; and 

  

	 	(v)	the appointment, removal or replacement of the CEO (or its equivalent). 

  

	8.10	Deadlock. 

  

	 	(a)	If the Board is unable to reach an agreement on any matter requiring Board approval set forth in clauses (m) through (v) of Section 8.9 in any two successive
meetings of the Board or within 30 days after such matter is first raised at a meeting of the Board, whichever is less (or if Section 8.13(b) is applicable with respect to such matter and the requisite Shareholder approval is not
obtained within 30 days after the matter giving rise to the disagreement has been raised) (the “Deadlock Date”), except as otherwise provided in Section 12.3(b), the disagreement with respect to such matter (the
“Deadlocked Matter”) shall be resolved pursuant to the procedures set forth in this Section 8.10. 

  

	 	(b)	Within 14 days after the Deadlock Date, either Party may deliver a deadlock notice (the “Deadlock Notice”) to the other Party stating that it has elected to invoke
the escalation procedures with respect to the relevant Deadlocked Matter. 

  

	 	(c)	The chief executive officer (or the Person holding the most senior management position) of each Party’s ultimate parent company, which in the case of DAP is GD and WTW is WWI,
shall meet with each other, either in person or by telephone, and attempt to resolve the relevant Deadlocked Matter within 30 days after the date of delivery of a Deadlock Notice. 

  

	 	(d)	If, after negotiation in good faith, the chief executive officers are unable to reach an agreement on the relevant Deadlocked Matter within a period of 30 days after the date on
which the Deadlock Notice is delivered, either Party (the “Invoking Party”) may elect to invoke the Deadlock Option within 14 days thereafter in accordance with the procedures set forth in Section 8.10(e).

  

 30 

	 	(e)	The “Deadlock Option” shall consist of the following: By written notice to the other Party (the “Non-Invoking Party”), the Invoking Party shall
give notice that it is invoking the Deadlock Option. Within 30 days of WTW sending such notice (if WTW is the Invoking Party) or within 30 days of WTW receiving such notice (if DAP is the Invoking Party), WTW shall deliver to DAP a notice (the
“Deadlock WTW Notice”) setting forth its determination of the value of its interest in the Company (the “Deadlock WTW Interest Value”). Upon receipt thereof, DAP must, by written notice (the “Deadlock
Exercise Notice”) to WTW delivered within 30 days following receipt of the Deadlock WTW Notice, either purchase the entire interest of WTW at a price equal to the Deadlock WTW Interest Value or sell its entire interest in the Company to WTW
at a price equal to the product of (i) the Deadlock WTW Interest Value, and (ii) a fraction, the numerator of which shall be the number of Shares held by DAP and the denominator of which shall be the number of Shares held by WTW. The
Exercise Notice shall be irrevocable and, together with the Deadlock WTW Notice, shall constitute a binding agreement by the Parties to purchase and sell the applicable interest of the selling Party in the Company. The closing of the sale of the
interest in the Company of DAP or WTW, as applicable, shall occur on a date to be determined by DAP, but in any event not later than 90 days following delivery to WTW of the Deadlock Exercise Notice. At such closing, the selling Party shall deliver
such duly executed instruments of transfer and other documents required in connection with such transfer and the purchasing Party shall deliver payment in full by wire transfer of immediately available funds. The interests being transferred shall be
free and clear of any Encumbrance (other than Encumbrances arising under this Agreement) and the selling Party shall so represent and warrant, and shall further represent and warrant that it is the beneficial and record owner of such interest being
transferred. 

  

	 	(f)	For the avoidance of doubt, WTW confirms that if following the exercise of the Deadlock Option in accordance with this Section 8.10, WTW transfers its entire interest in
the Company to DAP, the License Agreement shall not be deemed to be terminated and shall continue to be in effect in accordance with its terms and conditions. 

  

	 	(g)	For avoidance of doubt, if neither Party delivers a Deadlock Notice within 14 days after the Deadlock Date in accordance with Section 8.10(a) above with respect to any
Deadlocked Matter or the Deadlock Option is not exercised by any Party pursuant to Section 8.10(d) within the 14-day period specified therein, then such Deadlocked Matter shall be deemed disapproved by the Board and no further action
shall be taken by the Board or any Party hereunder. 

  

	8.11	Subsidiary Board and Committee. 

  

	 	(a)	 The Company shall cause each committee of the Board, and the board of directors of each Subsidiary (including each WFOE) and each committee thereof, to include
directors nominated by DAP and WTW 

  

 31 

	 	 
in the same proportion as each such Party is represented on the Board. The right of nomination of each such Party shall also carry the right to remove or
replace the director so nominated. 

  

	 	(b)	The Company shall cause the quorum and voting arrangements and other procedures with respect to each Subsidiary and its board of directors, as well as other corporate governance
matters, to be the same as those set forth in this Section 8 with respect to the Board and the Company. For the avoidance of doubt, the decisions requiring unanimous approval of the Board as set forth in Section 8.9 shall
apply to the board of directors of each Subsidiary with respect to actions to be taken by such Subsidiary. 

  

	 	(c)	The Parties shall cause the articles of association of each Subsidiary to provide that unanimous vote of all of the directors of such Subsidiary shall be required for such
Subsidiary to take any of the actions or omit to take any action that would have the effect of any of the actions specified in Section 8.9. Each Party shall cause its designees on the board of directors of each Subsidiary to vote with
respect to all matters as determined by the Board in accordance with this Section 8. 

  

	8.12	Shareholders Vote. Only matters that are required by applicable Laws of Hong Kong as amended from time to time, to be decided by the Shareholders shall be finally decided by
the Shareholders after and only after the approval of the Board is obtained with respect to such matters. All other matters in relation to the Company shall be finally decided by the Board without any requirement of Shareholder approval.

  

	8.13	Shareholders Meeting. 

  

	 	(a)	General. From the Company Establishment Date, each Shareholder shall vote its Shares at any regular or special meeting of Shareholders, and shall take all other actions
necessary, to give effect to the provisions of this Agreement and to ensure the inclusion in the Charter Documents of the rights and privileges of the Shareholders included in this Agreement. In addition, each Shareholder shall vote its Shares at
any Shareholders’ meeting, upon any matter submitted for action by the Shareholders or with respect to which such Shareholder may vote, in conformity with the specific terms and provisions of this Agreement and the Charter Documents.

  

	 	(b)	Quorum and Voting. The quorum for a Shareholders’ meeting shall be two Shareholders, being DAP and WTW. Decisions with respect to all matters that require approval of
Shareholders shall be adopted if they receive the affirmative vote of the Shareholders holding a simple majority of the Shares, provided that, to the extent that any of the actions specified in Section 8.9 are required by the laws
of Hong Kong to be approved by Shareholders, then, in addition to the unanimous approval of the Board, such actions shall also require the unanimous approval of the Shareholders. 

  

 32 

 SECTION 9 
 MANAGEMENT OF THE COMPANY 
  

	9.1	Management Structure. 

  

	 	(a)	The management organization of the Company shall consist of the following senior managers (the “Senior Managers”): one CEO, one Chief Financial Officer (the
“CFO”) and such other officers that the Board may designate from time to time as being necessary for the operation of the Company. 

  

	 	(b)	The initial CEO shall be nominated by WTW and appointed by unanimous approval of the Board as provided in Section 8.9. All subsequent CEOs shall be nominated and
appointed by unanimous approval of the Board as provided in Section 8.9. The CFO shall be nominated and appointed by the unanimous approval of the Board as provided in Section 8.9. The remaining Senior Managers shall be
appointed by the CEO. 

  

	 	(c)	The Board shall have the right to dismiss, remove and replace the CEO for any reason, by unanimous approval as provided in Section 8.9. The CEO shall have the right to
dismiss any other Senior Manager for any reason at any time. If the CEO or any of the other Senior Managers resigns, is dismissed or dies or becomes incapacitated, his successor shall be nominated and appointed in the same manner as stated in
Section 9.1(b). 

  

	9.2	CEO. 

  

	 	(a)	Subject to the direction and control of the Board, the CEO shall work full time and shall be responsible for the Company’s day-to-day operations. The CEO shall exercise the
rights and responsibilities conferred upon him or her by this Agreement, the Charter Documents or the Board and shall implement the resolutions of the Board. Without limiting the foregoing (but subject to Section 12.2), the CEO shall:

  

	 	(i)	prepare and submit to the Board for approval the Five-Year Business Plans and, at least 30 days prior to the beginning of each Financial Year, the Annual Plan for the Group;

  

	 	(ii)	prepare and submit to the Board financial statements regarding the Group’s operations in accordance with the provisions of Section 10.1(f) and in accordance with the
policies of the Group developed by the Board; and 

  

	 	(iii)	prepare a list of information relating to the Group which can be disclosed by the Parties or their respective Affiliates to the public, for approval by the Parties within 30 days
after the last day of each Financial Quarter (the list after being approved by the Parties, the “Approved Information”). 

  

 33 

	 	(b)	Subject to Section 8.9(k), the Board shall make all decisions with respect to the general compensation guidelines of Senior Managers, and the CEO shall determine the
amount of such compensation for management personnel within the set guidelines. The Company shall be responsible for all costs relating to the compensation of management personnel. 

  

	 	(c)	All the Senior Managers (other than the CEO) shall be under the leadership of, and report to, the CEO. The CEO shall determine the rights and responsibilities of each Senior Manager
in addition to those set forth in this Agreement or the Charter Documents. 

  

	9.3	CFO. 

  

	 	(a)	The CFO shall assist the CEO in managing the financial and accounting work of the Company and shall examine and sign the financial plans, credit plans, accounting reports, and major
expenditures of the Group. The CFO shall keep true and accurate records and accounts and prepare quarterly financial reports for the Board and other periodic financial statements as required by the Board, the CEO, any Party or applicable Laws. Such
reports and statements shall be prepared in accordance with (i) US GAAP, IFRS and the rules and regulations promulgated by the U.S. Securities and Exchange Commission in effect from time to time, and in accordance with the respective forms
and guidelines required by DAP and WTW in relation to the reports and statements prepared for such Party, (ii) HK GAAP for the Company if required for the statutory filings in HK and (iii) PRC GAAP for each PRC Subsidiary.

  

	 	(b)	The CFO shall also be in charge of examining and checking the financial receipts and payments, accounts and other information of the Group to verify that formalities are complied
with, records are accurate, revenue and expenditures are balanced and reasonable, the financial and accounting system of the Group (the “Financial and Accounting System”) is adhered to, and shall report on such matters to the CEO
and the Board. 

  

	9.4	Corporate Governance. 

  

	 	(a)	Each of the Parties agrees that the Company shall be managed in accordance with the highest international business ethical standards and that no director of the Board, Senior
Manager or other personnel of the Company will be permitted to engage in any act which violates applicable Law relating to corruption, bribery, fraudulent behavior or any other criminal activity. 

  

	 	(b)	 The Company and its Representatives shall engage only in legitimate business and ethical practices in commercial operations and in relation to government
authorities. Neither the Company nor any of its Representatives shall make any payments or transfers of value which have the purpose or effect of public or commercial bribery, or 

  

 34 

	 	 
acceptance of or acquiescence in kickbacks or other unlawful or improper means of obtaining business. Neither the Company nor any of its Representatives
shall pay, offer, promise or authorize the payment, directly or indirectly, of any funds or anything of value to any government official or employee or any political party for the purpose of influencing any act or decision of such official or of the
government to obtain or retain business, or direct business to any Person (any such act, a “Prohibited Payment”). A Prohibited Payment does not include the payment of reasonable and bona fide expenditures, such as travel and lodging
expenses, that are directly related to the promotion, demonstration or explanation of products or services, or the execution or performance of a contract with a government authority or agency thereof, provided that such payments are permissible
under Law and the internal policies and guidelines of the Company. Without limiting the generality of the foregoing, neither the Company nor any of its Representatives shall engage in any activities or practices that are in violation of the U.S.
Foreign Corrupt Practices Act of 1977, as amended, or any other anti-corruption or anti-bribery Laws applicable to the Parties or the Company. 

  

	 	(c)	Each Party hereby represents and undertakes to the other Party that, in connection with the performance of its obligations under this Agreement, such Party and its Representatives,
have not, and will not, pay, offer, promise or authorize, directly or indirectly, any Prohibited Payment. 

  

	 	(d)	The Company shall ensure that all of the management provisions set forth in this Section 9 shall apply with respect to the management of each Subsidiary.

 SECTION 10 
 FINANCIAL, ACCOUNTING AND AUDITING SYSTEM 
  

	10.1	Financial System and Reporting. 

  

	 	(a)	The Financial and Accounting System of the Group shall be formulated and adopted by the Board based on the recommendations of the CEO, which shall be prepared based on suggestions
of the CFO, and shall be in accordance with any applicable Laws, the particular circumstances of the Company and those methods and principles that are consistent with (i) US GAAP, IFRS and the rules and regulations promulgated by the U.S.
Securities and Exchange Commission in effect from time to time, (ii) HK GAAP in relation to the Company if required for the statutory filings in HK, (iii) PRC GAAP in relation to the PRC Subsidiaries, and (iv) the operating and
financial procedures and requirements of DAP and WTW in relation to the preparation of the financial reports and statements required by such Party. 

  

	 	(b)	The Financial and Accounting System shall be implemented by the CFO after being approved by the Board. 

  

 35 

	 	(c)	The Company shall use HK$ as its accounting unit. The PRC Subsidiaries shall use RMB as their accounting unit and the non-PRC Subsidiaries shall also use HK$ as their accounting
unit. Cash, bank deposits and funds in other currencies, as well as outstanding claims and debts, gains, expenses and so forth in other currencies, shall be recorded in the actual currency in which they are acquired, incurred, received or disbursed,
and converted into HK$ for Company accounting purposes. The conversion of foreign currencies into or from HK$ for accounting purposes shall be calculated according to the average of the buying and selling rates quoted by the Hong Kong and Shanghai
Banking Corporation for the relevant currency on the date of the relevant transaction, unless the Board approves the use of another exchange rate for such conversions. 

  

	 	(d)	The Company shall open bank accounts with financial institutions approved by the Board. 

  

	 	(e)	The Company shall adopt the internationally used accrual basis and debit and credit accounting system, and other methods that are consistent with US GAAP, IFRS and the rules
and regulations promulgated by the U.S. Securities and Exchange Commission in effect from time to time, in the keeping of accounts, and in relation to the Company, also consistent with the HK GAAP for statutory filings purposes and in relation to
the PRC Subsidiaries, the PRC GAAP. 

  

	 	(f)	The financial statements prepared for the Company shall be prepared on a consolidated basis, which shall consist of the balance sheets, the statement of operations, the statement of
changes in shareholders equity, and the statement of cash flow. All financial statements shall be prepared in English, in accordance with both US GAAP and IFRS, shall be true and complete and shall fairly represent the financial position of the
Group as of the date of each such statement and the results of operations and cash flow for the financial period covered thereby, subject in the case of unaudited statements to normal year-end audit adjustments. 

  

	 	(g)	The Company shall submit quarterly financial statements to the Board within 30 days after the last day of each Financial Quarter. Within 45 days after the last day of the second
Financial Quarter, the Auditor will perform an interim review and submit the results thereof to the Board. The Company shall submit annual financial statements, including the Auditor’s report of its audit of such statements, to the Board within
45 days after the last day of each Financial Year. The Parties agree that the Company shall use reasonable efforts to submit monthly financial statements to the Board within 30 days after the last day of each monthly accounting period, commencing
after such date as the Company determines that it has staff and resources such that it is reasonably practicable for it to do so. 

  

 36 

	 	(h)	Within 45 days after the last day of each Financial Year, the Company shall deliver to the Parties such financial reports and information regarding the activities and operations of
the Company and each Subsidiary (including each WFOE) with respect to the preceding Financial Year as reasonably requested by the Parties. This information shall be supplemented by timely delivery to the Parties of such additional financial
information, and access to personnel, as may be reasonably requested by the Parties. 

  

	10.2	Audit. The independent auditor of the Company (the “Auditor”) shall be selected by the Board and shall be one of the four major international accounting
firms with an office established in the PRC who is capable of performing accounting work meeting both PRC domestic accounting standards and international standards and the procedures and requirements of the Parties, including those specified in
Section 10.1(a). The initial Auditor shall be PricewaterhouseCoopers. If the Board determines that the Auditor is unable to meet or perform its duties according to such standards, procedures or requirements, it may, subject to
Section 8.9(e), replace such Auditor or retain another auditor, at the Company’s expense, to supplement or adjust the work of the Auditor or to perform specific accounting or auditing tasks. 

  

	10.3	Taxation. 

  

	 	(a)	The Company shall pay taxes in accordance with applicable Law. The Parties agree to negotiate in good faith any cooperative arrangements that would result in the maximization of the
tax benefits available to each of the Parties and the Company, and that any such cooperative arrangement may be varied based on good faith negotiations between the Parties if such variation is required to so maximize such tax benefits;
provided that, any such cooperative arrangement shall not be varied if it may result in any taxation or other financial consequence that is disadvantageous to either DAP, WTW, the Company or any of their respective Affiliates, provided
further that, the Company shall seek to minimize the overall tax burden of the Group irrespective of any deduction or credit permitted under the License Agreement against royalties paid to WWI with respect to withholding or business taxes that
may be imposed on royalties paid by any Subsidiary of the Company to the Company. In furtherance of the foregoing, the Parties agree, upon the request of WTW, to consent to join in and to permit the Company and/or its Subsidiaries to make
“check the box” elections to treat the Company or any of its Subsidiaries as fiscally transparent for U.S. federal income tax purposes. 

  

	 	(b)	The Parties shall assist the Company in applying to obtain the benefits for the Company, the Parties and all of their personnel of all of the applicable tax exemptions, reductions,
privileges and preferences that are now or in the future become available under applicable Laws and under any applicable treaties or international agreements to which Hong Kong may now be or may hereafter become a party. 

  

 37 

	10.4	Securities Laws Compliance. 

  

	 	(a)	The Company shall cooperate with WTW and its Representatives to provide WTW access to such information related to the internal controls and the disclosure controls and procedures of
the Company as may be needed by WTW to comply with its (ii) obligations to file any certifications required under the Sarbanes-Oxley Act of 2002 (“SOXA”) and any reports on internal controls over financial reporting required
under SOXA for each Financial Year during the term of this Agreement and (ii) its other obligations under the rules and regulations promulgated by the U.S. Securities and Exchange Commission in effect from time to time and the rules promulgated
by the New York Stock Exchange in effect from time to time (collectively, the “Securities Laws Obligations”). The costs and expenses associated with access to such information, including the cost of copying any documents or records
permitted by the Company to be copied, shall be borne by WTW. 

  

	 	(b)	Upon the written request of WTW, the Company shall request that the Auditor prepare and deliver to WTW any other documents or reports required for WTW to satisfy any Securities Law
Obligation. The out-of-pocket costs incurred by the Company (including the cost of the Auditor) as a result of the preparation and delivery of such document or report shall be borne by WTW. 

  

	10.5	Insurance. The Company shall, and shall ensure that each Subsidiary shall, keep insured at all times and maintain insurance policies in a sufficient amount and with such
coverage as are generally maintained by responsible companies in the same industry. Such policies shall be sufficient to cover liabilities to which the Group may reasonably be considered at risk in the course of their respective businesses. Without
limiting the generality of the foregoing, the Company shall, and shall ensure that each Subsidiary shall, (i) keep insured up to the replacement value thereof (including surveyor’s and architect’s fees) all its properties as are of an
insurable nature against fire, theft, lighting, explosion, earthquake, riot, strike, civil commotion, storm, tempest, flood, marine risks, erection risks, war risks and such other risks and shall duly pay all premia and other sums payable for those
purposes and (ii) maintain a directors and officers insurance policy of a scope and type reasonably acceptable to the Shareholders and for the insured amount of at least US$5,000,000. Such insurance shall be taken in the name of the Company or
Subsidiary, as applicable, and any other Person having an insurable interest in the property of the Company or the Subsidiary, as the case may be. The Company agrees that in the event of failure on the part of the Company or any Subsidiary to insure
the properties or to pay the insurance premia or other sums referred to above, any Shareholder may (but shall not be obliged to) cause the properties to be insured or pay the insurance premia or other sums referred to above, as the case may be, and
the Company shall promptly reimburse any expense incurred by such Shareholder in taking such action. 

  

 38 

 SECTION 11 
 PROFIT DISTRIBUTIONS 
  

	11.1	Dividends. 

  

	 	(a)	Subject to the other provisions of this Section 11, the Company shall distribute to the Parties by way of a dividend at least 50% of the Distributable Profits of the
Group in respect of each Financial Year, and unless a different percentage is agreed to by the Board on a unanimous basis. 

  

	 	(b)	The Board shall make such plans as it deems desirable for the accumulation, distribution or investment of profits remaining after paying income tax and making allocations to any
relevant reserve funds in accordance with any applicable Laws. 

  

	 	(c)	The Company may not distribute profits until the losses of the previous Financial Years have been made up and the due and payable principal of and accrued interest on all
Shareholders’ loans, if any, have been repaid in full. 

  

	 	(d)	Undistributed profits from previous Financial Years may be distributed together with the profits of the current Financial Year. 

 SECTION 12 
 BUDGETS AND BUSINESS
PLAN 
  

	12.1	Five-Year Plan. The activities and operations of the Group shall be conducted in accordance with a Five-Year Business Plan, which shall be subject to the approval of the
Board on a unanimous basis as provided in Section 8.9. Each Five-Year Business Plan shall include a set of key performance indicators (“KPIs”) and, except for the initial Five-Year Business Plan, a set of minimum
performance thresholds (“MPTs”). The KPIs shall reflect the key financial, operating and performance statistics, criteria or indicators that the Five-Year Business Plan is targeting for the performance of the Group each year. The
MPTs shall reflect the minimally acceptable key financial, operating and performance statistics, criteria or indicators for the time period covered by the Five-Year Business Plan. Upon the approval of the applicable Five-Year Business Plan, the KPIs
and the MPTs included therein shall also be deemed approved. 

  

	12.2	Initial and Updated Five-Year Plans. Each Party shall cause the directors appointed by it to vote at the first meeting of the Board to adopt a resolution approving the
initial Five-Year Business Plan that was mutually agreed by the Parties. Not later than three months prior to the end of the period covered by the then-current Five-Year Business Plan or such other time as agreed by the Parties, the CEO shall submit
an updated Five-Year Business Plan to the Board for its approval. In the event that the updated Five-Year Business Plan is not approved by the end of the period covered by the then-current Five-Year Business Plan, the Group shall continue to operate
in accordance with the annual budget of the last approved Annual Plan until the disagreement with respect to the updated Five-Year Business Plan is finally resolved in accordance with the procedures described in Section 8.10.

  

 39 

	12.3	Annual Plans. 

  

	 	(a)	An annual financial and operating plan for the Group, including an annual budget for each Financial Year (the “Annual Plan”) based on the Five-Year Business Plan
shall be submitted by the CEO to the Board for its approval not later than the end of the second week of the last calendar month (“Deadline”) of the immediately preceding Financial Year. 

  

	 	(b)	If the proposed Annual Plan for the Financial Year is projected to fail to meet or exceed any of the KPIs or MPTs (if any) for such year, such Annual Plan shall not be adopted
without the unanimous approval of the Board. However, if such projected failure is due solely to the failure to satisfy any of the KPIs and, as a result, the Annual Plan is not unanimously approved by the Board, DAP shall not have the right to
exercise the Deadlock Option under Section 8.10, but instead the matter shall be resolved by the chief executive officer or the chief operating officer of WWI. For the avoidance of doubt, if the proposed Annual Plan for the Financial
Year is projected to fail to meet or exceed any of the MPTs for such year (regardless of whether the Annual Plan meets or exceeds the KPIs), such Annual Plan shall not be adopted without the unanimous approval of the Board and the Deadlock Option
will apply if such approval is not obtained. 

  

	 	(c)	If the actual performance of the Group during any Financial Year fails to meet or exceed any of the MPTs for such year (based on numbers available on the Deadline and the projected
numbers for the period starting from the Deadline and ending on the last day of the Financial Year), the Annual Plan for the following Financial Year shall not be adopted without the unanimous approval of the Board, and DAP’s right to exercise
the Deadlock Option under Section 8.10 shall apply if such approval is not obtained unless the failure to meet or exceed any of the MPTs was contemplated when the applicable Annual Plan was unanimously approved by the Board. Nothing in
this Section 12.3(c) shall preclude DAP from exercising its rights under Section 15 with respect to the Milestones to be reached. 

  

	 	(d)	If the Board has not approved the applicable Annual Plan by the Deadline, the annual budget (as set forth in the last approved Annual Plan) shall continue to apply for the first
three (3) months of the subsequent Financial Year. In the event that such Annual Plan is not approved within the first three months of the subsequent Financial Year, DAP’s right to exercise the Deadlock Option under
Section 8.10 shall apply, provided that, prior to the final resolution of the deadlock provisions and procedures in accordance with Section 8.10, the Company and each WFOE shall be able to operate its business in accordance
with the annual budget of the last approved Annual Plan. 

  

 40 

 SECTION 13 
 TERM, TERMINATION AND LIQUIDATION 
  

	13.1	Company Term. This Agreement shall enter into effect on the date hereof and, unless terminated by the written agreement of the Parties, shall continue for so long as two or
more Shareholders continue to hold interests in the Company. This Agreement shall be terminated with respect to any Shareholder who has Transferred all of its Equity Securities in the Company to a third party. 

  

	13.2	WFOE Term. 

  

	 	(a)	The term of operations of each WFOE (as extended from time to time, each a “WFOE Term”) shall initially be 30 years commencing on the WFOE Establishment Date of
such WFOE and shall be extended for successive 30 year periods in accordance with the articles of association of such WFOE unless earlier terminated pursuant to this Section 13. 

  

	 	(b)	An application for extension of the WFOE Term for each WFOE shall be filed with the Examination and Approval Authority not later than six months prior to the expiration of the WFOE
Term for such WFOE for the extension of the WFOE Term for such WFOE, and the Parties shall, and shall ensure that their Affiliates will extend the terms of the License Agreement and Other Agreements to which they are parties for the same number of
years as the WFOE Term for such WFOE will be extended, subject in each case to the termination provisions thereof. 

  

	13.3	Termination. 

  

	 	(a)	This Agreement shall automatically terminate upon one Party owning all of the Equity Securities of the Company. 

  

	 	(b)	The Company may be dissolved according to the terms of the Charter Documents and this Agreement terminated upon the motion of the Party indicated below if any of the conditions or
events set forth below shall occur and be continuing: 

  

	 	(i)	upon the motion of either Party, should the Parties mutually agree to dissolve the Company; or 

  

	 	(ii)	upon the motion of either Party, if any of the Initial Conditions has not been satisfied on or prior to the Long Stop Date. 

  

 41 

	 	(c)	The Company may be dissolved according to the terms of the Charter Documents, and this Agreement terminated, upon the motion of the Party indicated below (the “Terminating
Party”) if (1) any of the conditions or events set forth below shall occur and be continuing and (2) the Terminating Party does not exercise its Termination Purchase Right: 

  

	 	(i)	upon the motion of the solvent Party, should the other Party become bankrupt or insolvent or file a petition seeking protection under any bankruptcy, reorganization or insolvency
Law; 

  

	 	(ii)	upon the motion of the non-breaching Party, should the other Party breach any of its material obligations under this Agreement, and if such breach is capable of being remedied, such
breach is not remedied within 30 days after the date on which a notice of such breach is delivered by the non-breaching Party to the breaching Party; or 

  

	 	(iii)	upon the motion of any Party, in the event of a material breach of the Confidentiality Agreement by the Affiliate of the other Party who is a party to the Confidentiality Agreement,
and if such breach is capable of being remedied, such breach is not remedied within the time period specified in the Confidentiality Agreement. 

  

	 	(d)	Subject to Section 14.4, this Agreement shall terminate in the event of termination of the License Agreement, in which case either Party shall have the right to make a
motion to dissolve the Company. 

  

	 	(e)	If either Party makes a motion to dissolve the Company pursuant to a right granted to it in Section 13.3(b), 13.3(c), 13.3(d) or elsewhere in this
Agreement, each Party shall cause the directors appointed by it to adopt a resolution in favor of the dissolution of the Company. 

 SECTION 14 
 PURCHASE UPON TERMINATION 
  

	14.1	Termination Buyout Right. If the termination of this Agreement arises as a result of any event described in Section 13.3(c), the Terminating Party shall have the
right (the “Termination Purchase Right”) to purchase the entire equity interest in the Company of the other Party (the “Non-Terminating Party”) in accordance with this Section 14.

  

	14.2	 Exercise of Buyout Right. The Termination Purchase Right shall be exercised as follows: The Terminating Party shall, by written notice (the “Buyout
Notice”) to the Non-Terminating Party, notify the Non-Terminating Party that it elects to purchase the entire interest of the Non-Terminating Party in the Company at a price equal to the Applicable Buyout Price and otherwise in accordance
with this Section 14. The Buyout Notice shall be irrevocable and, upon delivery of same to the Non-Terminating Party, shall constitute a binding agreement by the Parties to purchase and sell the interest of the Non-Terminating Party in
the Company. The closing of the sale of the interest in the Company shall occur on a date to be determined by the Terminating Party, but in any event not later than two (2) months following delivery of the Buyout Notice. At such closing, the
Non-Terminating Party shall deliver such duly executed instruments of transfer and other documents required in connection with such transfer and the Terminating Party shall deliver payment 

  

 42 

	 	 
in full by wire transfer of immediately available funds. The interests being transferred shall be free and clear of any Encumbrance (other than Encumbrances
arising under this Agreement) and the Non-Terminating Party shall so represent and warrant, and shall further represent and warrant that it is the beneficial and record owner of such interest being transferred. 

  

	14.3	License Agreement to Remain in Effect. For the avoidance of doubt, WTW confirms that if DAP exercises its Termination Purchase Right in accordance with
Section 14.1 and purchases WTW’s entire interest in the Company, the License Agreement shall not be deemed to be terminated and shall continue to be in effect in accordance with its terms and conditions. 

  

	14.4	DAP Termination Right. If the termination of this Agreement arises as a result of the termination of the License Agreement, WTW must purchase the entire interest of DAP in
the Company at a price equal to the WTW Buyout Price. The closing of the sale of the interest in the Company shall occur on a date to be determined by WTW, but in any event not later than two (2) months following the termination of the License
Agreement. At such closing, DAP shall deliver such duly executed instruments of transfer and other documents required in connection with such transfer and WTW shall deliver payment in full by wire transfer of immediately available funds. The
interests being transferred shall be free and clear of any Encumbrance (other than Encumbrances arising under this Agreement) and DAP shall so represent and warrant, and shall further represent and warrant that it is the beneficial and record owner
of such interest being transferred. 

 SECTION 15 
 MILESTONES 
  

	15.1	Milestone Buyout Right. The Parties have agreed on achieving certain milestones, to be set forth in the initial Five-Year Business Plan (the “Milestones”).
With respect to the second and third Milestones, within 30 days of the end of the relevant Milestone period, the Company shall instruct the Auditor to verify in writing whether the Milestones have been reached by the WFOEs. In the event such
Milestones are not reached by the WFOEs (as determined by the Auditor, where applicable), DAP shall have the right (the “Milestone Failure Purchase Right”) to sell its entire interest in the Company to WTW in accordance with this
Section 15. 

  

	15.2	Exercise of Buyout Right. 

  

	 	(a)	 The Milestone Failure Purchase Right shall be exercised as follows. Within 30 days of receiving the Company’s notice of the Milestone failure, DAP shall have
the right, by written notice (the “Milestone Buyout Notice”) to WTW, to notify WTW that it elects to sell the entire interest of DAP in the Company to WTW at a price equal to the WTW Buyout Price and otherwise in accordance with
this Section 15. The Milestone Buyout Notice shall be irrevocable and, upon delivery of same to WTW, shall constitute a binding agreement by the Parties to purchase and sell the interest of DAP in the Company. The closing of the sale of
DAP’s interest in the Company shall occur on a date to be 

  

 43 

	 	 
determined by WTW, but in any event not later than two (2) months following delivery of the Milestone Buyout Notice. At such closing, DAP shall deliver
such duly executed instruments of transfer and other documents required in connection with such transfer and WTW shall deliver payment in full of the WTW Buyout Price by wire transfer of immediately available funds. The interests being transferred
shall be free and clear of any Encumbrance (other than Encumbrances arising under this Agreement) and DAP shall so represent and warrant, and shall further represent and warrant that it is the beneficial and record owner of such interest being
transferred. 

  

	 	(b)	Notwithstanding the above, in the event that the failure to reach any of the Milestones was contemplated by the Annual Plan and the Annual Plan was approved by the Board on a
unanimous basis, DAP shall not have the right to sell DAP’s interests in the Company as provided in this Section 15. 

 SECTION 16 
 LIABILITY FOR BREACH OF CONTRACT 
  

	16.1	Liability. Subject to the provisions of this Section 16, a Party shall be in breach of this Agreement or any Other Agreement to which it is a party (a) if it
fails to perform, or suspends its performance of, its obligations under this Agreement or such Other Agreement to which it is a party, and if it does not commence correction of such failure within 30 days, and complete such correction within 60
days, following receipt of written notice of such failure from the other Party or the Company, which notice must specify the nature of the alleged breach in reasonable detail; or (b) if any of the representations and warranties made by such
Party hereunder or in any of the Other Agreements to which it is a party is untrue or inaccurate in any material respect. 

 SECTION 17 
 GOVERNING LAW AND DISPUTE RESOLUTION 
  

	17.1	Governing Law. This Agreement and all claims (including claims based in contract, statute or tort) arising out of or relating to this Agreement, its interpretation, validity
and enforcement shall be (a) governed by, and construed and interpreted in accordance with, the laws of Hong Kong and (b) resolved solely pursuant to binding arbitration. 

  

	17.2	Dispute Resolution. 

  

	 	(a)	The Parties shall attempt to resolve any Dispute through friendly consultation. Such consultation shall begin immediately after one Party has delivered to the other Party a written
request for such consultation stating specifically the nature of the Dispute. If within 30 days following the date on which such notice is given the Dispute cannot be resolved, the Dispute shall be referred to, and finally resolved by, arbitration
upon the request of any Party with notice (the “Submission Notice”) to the other Party. Any dispute related to a Deadlocked Matter shall be resolved in accordance with the principles and procedures set forth in
Section 8.10 and Section 12.2, respectively, and shall not be subject to the provisions of this Section 17.2. 

  

 44 

	 	(b)	The arbitration shall be conducted in Hong Kong under the auspices of the Hong Kong International Arbitration Centre (“HKIAC”) and in accordance with the
Arbitration Rules as at present in force save as modified in this Agreement. There shall be three arbitrators. DAP shall select one arbitrator, and WTW shall select one arbitrator. All selections shall be made within 30 days after the selecting
Party gives or receives the demand for arbitration. Such arbitrators shall be freely selected, and each Party shall not be limited in its selection to any prescribed list. The third arbitrator shall be jointly selected by the arbitrators selected by
DAP and WTW. If the arbitrators selected by DAP and WTW fail to select the third arbitrator within 30 days after the date on which the arbitrators for both DAP and WTW have been selected, the HKIAC shall select the third arbitrator.

  

	 	(c)	The arbitration proceedings shall be conducted in English. The arbitration tribunal shall apply the Arbitration Rules as are in force at the time of the arbitration. However, if
such rules are in conflict with the provisions of this Section 17, the provisions of this Section 17 shall prevail. The award of the arbitration tribunal shall be final and binding upon the Parties, and the winning Party may
apply to any court of competent jurisdiction for enforcement of such award. In order to preserve its rights and remedies, any Party shall be entitled to seek preservation of property in accordance with any applicable Law in any court of competent
jurisdiction or from the arbitration tribunal pending the final decision or award of the arbitration tribunal. During the period when the Dispute is being resolved, except for the matters being disputed, the Parties shall in all other respects
continue their implementation of this Agreement, provided that, the Dispute does not relate to a matter under Section 13.3. 

  

	 	(d)	Each Party irrevocably consents to the service of process, notices or other papers in connection with or in any way arising from the arbitration or the enforcement of any arbitral
award, by use of any of the methods and to the addresses stipulated in Section 19.11. Nothing contained herein shall affect the right of any Party to serve such process, notices or other papers in any other manner permitted by applicable
Law. 

 SECTION 18 
 REPRESENTATIONS AND WARRANTIES 
 Each Party represents and warrants to the other Party, with respect to itself, as of the date of this
Agreement and as a continuing representation during the period that the Party owns an interest in the Company, as follows: 
  

	 	(a)	Such Party is a company duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation, and has the corporate power and lawful
authority to own or possess, lease and operate its assets and to carry on its business as now being and as previously conducted. 

  

 45 

	 	(b)	Such Party has the full legal right, power and authority required to enter into this Agreement and to perform fully its obligations hereunder. This Agreement has been duly
authorized, executed and delivered by such Party and, assuming the due authorization, execution and delivery by the other Party, constitutes the valid and binding obligation of such Party enforceable against it in accordance with its terms.

  

	 	(c)	Except as otherwise set forth in this Agreement, no filings with, notices to, or license, permits, consents, authorizations, qualifications, orders or other approvals of any
governmental authority or any other Person are necessary to be obtained by such Party for its execution, delivery and performance of this Agreement or for the establishment of the Company. 

  

	 	(d)	Such Party is, has been and will continue to be in compliance in all material respects with all applicable Laws of its jurisdiction of incorporation and does not know of any
circumstances that would be a breach of any such Laws. 

  

	 	(e)	Neither the execution of this Agreement, nor the performance of such Party’s obligations hereunder, will conflict with, or result in a breach of, or constitute a default under,
any provision of the memorandum and articles of association (or similar organizational documents), business license or bylaws of such Party, as the case may be, or any applicable Laws or of any contract or agreement to which such Party is a party or
is subject. 

  

	 	(f)	As of the date of this Agreement, there is no lawsuit, arbitration or legal, administrative or other proceeding or governmental investigation pending or, to the best knowledge of
such Party, threatened against such Party with respect to the subject matter of this Agreement or that would affect in any way such Party’s ability to enter into or perform this Agreement, and if any such lawsuit, arbitration or legal,
administrative or other proceeding or governmental investigation should come to the knowledge of either Party after the date of this Agreement it shall promptly notify the other Party and provide the other Party with detailed information with
respect to such matter. 

  

	 	(g)	 There is no document, statement or information of, or derived from, any governmental body in the possession of such Party that has not been disclosed to the other
Party, which if disclosed, would materially adversely affect such other Party’s decision to enter into this Agreement or to consummate the transactions contemplated herein. Furthermore, all material documents, statements and information, which
have a material impact on the business, operations or affairs of the Group will be promptly disclosed to the other Party to the extent that they first come to the attention to such Party after the date of this 

  

 46 

	 	 
Agreement. The documents previously provided by such Party to the other Party, taken as a whole, do not contain any untrue statement of a material fact or
omit to state any material fact necessary in order to make the statements contained therein not misleading. 

 SECTION 19

 EFFECTIVENESS OF THE CONTRACT AND MISCELLANEOUS 
  

	19.1	Binding Effect. This Agreement shall be binding upon the permitted successors and assigns of the Parties. 

  

	19.2	Notice of Breach. Any of the Parties that becomes aware of a fact that has occurred, which could in any way adversely affect or impair the fulfillment of any of the
obligations undertaken herein in any material respect, shall promptly inform the other Party of such fact. 

  

	19.3	Entire Agreement. This Agreement, together with the License Agreement, the Charter Documents and the Other Agreements, constitutes the entire agreement between the Parties
with respect to the subject matter hereof. 

  

	19.4	Amendment. This Agreement shall not be amended, altered or changed except by a written agreement signed by the Parties. Unless expressly agreed, no amendment shall constitute
a general waiver of any provisions of this Agreement, nor shall it affect any rights, obligations or liabilities under or pursuant to this Agreement which have already accrued up to the date of amendment, and the rights and obligations of the
Parties under or pursuant to this Agreement shall remain in full force and effect, except and only to the extent that they are so amended. 

  

	19.5	Waiver. No delay on the part of any Party in exercising any right hereunder shall operate as a waiver thereof, nor shall any waiver, express or implied, by any Party of any
right hereunder or of any failure to perform or breach hereof by any other Party constitute or be deemed a waiver of any other right hereunder or of any other failure to perform or breach hereof by the same or any other Party, whether of a similar
or dissimilar nature. Failure of a Party to exercise any of its rights under this Agreement shall in no way be considered a waiver of the right to so exercise at any later time. 

  

	19.6	Severability. If any provision of this Agreement is or is held to be invalid or unenforceable, then to the extent of its invalidity or unenforceability it shall have no
effect and shall be deemed not to be included in this Agreement, and the remaining provisions of this Agreement shall not be invalidated. The Parties shall then use all reasonable efforts to replace the invalid or unenforceable provision by a valid
provision the effect of which is as close as practicable to the intended effect of the invalid or unenforceable provision. 

  

	19.7	No Agency. Nothing in this Agreement (or any of the arrangements contemplated by it), save as may be expressly set out in it, constitute any Party the agent of the other
Party for any purpose. Unless the Parties agree otherwise in writing, none of them shall (a) enter into contracts with any Person as agent for the other Party or (b) describe itself as such an agent or in any way hold itself out as being
such an agent. 

  

 47 

	19.8	 Counterparts. This Agreement may be executed in any number of counterparts and by the Parties to it on separate counterparts,  each of which shall be an original but all
of which together shall constitute one and the same instrument. 

  

	19.9 	Language. This Agreement shall be drafted and executed in the English language. 

  

	19.10 	Survival. The agreements of the Party contained in Sections 7, 16 and 17, and this Section 19 shall continue to survive after the
expiration or termination of this Agreement and the dissolution of the Company. 

  

	19.11 	Notices. All notices, requests, demands, claims and other communications hereunder shall be in writing. Any notice, request, demand, claim or other communication hereunder
shall be deemed duly delivered four Business Days after it is sent by registered or certified mail, return receipt requested, postage prepaid, or two Business Days after it is sent for next business day delivery via a reputable international
overnight courier service, or deemed dispatched immediately after it is sent by facsimile transmission properly addressed and dispatched and a transmission report confirming dispatch is received, in each case to the intended recipient as set forth
below. 

  

					
	 If to the Company:
	 	12/F, Ruttonjee House, 11 Duddell Street,
		 	Central, Hong Kong
		 	Attention:	  	Chief Executive Officer
		 	Facsimile:	  	(852) 2845 9198
		
	 If to DAP:
	 	 c/o Danone Asia-Pacific Management Co., Ltd.

		 	 19th Floor, Kerry Center

		 	 1515 Nanjing Road (W)

		 	 Shanghai 200040, PRC

		 	Attention:	  	David Flavell, General Counsel
		 	Facsimile:	  	86-21-5298-6800
		
	 with a copy to:
	 	 Baker & McKenzie

		 	 Unit 1601, Jin Mao Tower

		 	 88 Century Avenue

		 	 Pudong, Shanghai 200121

		 	Attention:	  	Howard H. Wu
		 	Facsimile:	  	86-21-5047-0020
		
	 If to WTW:
	 	 11 Madison Avenue, 17th Floor

		 	 New York, NY 10010

		 	Attention:	  	David Kirchhoff, CEO
		 	Facsimile:	  	(212) 589-2859
		
	 with a copy to:
	 	 11 Madison Avenue, 17th Floor

		 	 New York, NY 10010

		 	Attention:	  	Jeffrey Fiarman, General Counsel
		 	Facsimile:	  	(212) 589-2601

  

 48 

					
	 with a copy to:
	 	 Paul, Weiss, Rifkind, Wharton & Garrison

		 	 12th Floor, Hong Kong Club Building

		 	 3A Chater Road Central

		 	 Hong Kong

		 	Attention:	  	Jeanette K. Chan
		 	Facsimile:	  	852-2536-9622

 Any Party may give any notice, request, demand, claim, or other communication hereunder using any other means
(including personal delivery, expedited courier, messenger service, telecopy, ordinary mail, or electronic mail), but no such notice, request, demand, claim or other communication shall be deemed to have been duly given unless and until it is
received by the Party for whom it is intended. Any Party may change the address to which notices, requests, demands, claims and other communications hereunder are to be delivered by giving the other Party notice in the manner herein set forth. Any
notice, request, demand, claim, or other communication hereunder or in connection with this Agreement shall be in the English language or, if in any other language, accompanied by a translation into English. In the event of any conflict, the English
version shall prevail. 
 [THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK] 
  

 49 

 IN WITNESS WHEREOF, the Parties have caused their respective representatives to execute this Agreement as
of the date first above written. 
  

					
	DANONE DAIRY ASIA
		
	By:	 	/s/ Thomas Rondot
		 	Name:	 	Thomas Rondot
		 	Title:	 	
	
	WEIGHT WATCHERS ASIA HOLDINGS LTD.
		
	By:	 	/s/ David P. Kirchhoff
		 	Name:	 	David P. Kirchhoff
		 	Title:	 	President

  

 50

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}]]